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Abstract: Illicit opioid consumption is associated 
with a sixfold increase in obstetric complications 
in pregnant women. Neonatal complications 
include narcotic withdrawal, postnatal growth 
deficiency, microcephaly, neurobehavioural 
problems, increase in neonatal mortality and a 
74-fold increase in sudden infant death 
syndrome. The primary goal of treatment for 
opioid dependence in pregnant women is to 
stabilise the patient, in order to avoid the 
permanent fluctuation of plasma levels and 
related foetal consequences, such as foetal 
distress and preterm birth. Psychosocially 
assisted opioid substitution treatment is the 
first-line treatment for opioid dependence in 
pregnant women, and several combinations of 
substitution medicines and psychosocial 
approaches are available. The pharmacological 
interventions studied in this overview were 
methadone, buprenorphine and slow-release oral 
morphine; the psychosocial interventions were 
cognitive behaviour approaches and contingency 
management. The observed differences between 
the three substitution approaches did not show a 
homogeneous and comprehensive pattern to 
conclude that one treatment is superior to the 
others for all relevant outcomes. While 
methadone seems superior in retaining patients 
in treatment, buprenorphine seems to yield to 
less severe neonatal abstinence syndrome and 
higher birth weight.
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Republic reported a prevalence of 1.8 % of illicit drug use 
among over 1 million mothers between 2000 and 2009.
Although it is difficult to estimate the real prevalence, the 
problem of pregnant drug users is known by those working in 
the field and it is important to accurately address it for several 
reasons. Firstly, pregnant women may shy away from health 
services for fear of the consequences on their parental rights; 
secondly, they may wish to quit drugs and treatment in an 
uncontrolled way, which can be riskier than remaining in 
pharmaceutically assisted treatment; and, finally pregnancy 
has been described as a ‘window of opportunity’ for drug 
users to take care of their health (Daley et al., 1998).
I Risks of opioid use during pregnancy
All psychoactive drugs, including alcohol, tobacco and some 
prescribed medications, may have adverse effects on the 
pregnancy, the unborn child and the newborn. However, 
different drugs may act differently (Table 1). This may be a 
result of not only the drug itself, but also the poor overall 
health and nutritional status of the drug-using expectant 
woman. The degree of the impact of drug use during 
pregnancy largely depends on the intensity of drug use, which 
is complicated by the fact that patients frequently abuse more 
than one licit or illicit substance (Goel et al., 2011; Havens et 
al., 2009) and up to 97 % of opioid-dependent pregnant 
women are smokers (Jones et al., 2011). 
I Background
The true prevalence of drug use among pregnant women in 
Europe is difficult to ascertain, and differences across 
countries or in certain areas may exist. In reality, data on the 
prevalence of illicit drug use among pregnant women are not 
available for most European countries. Information made 
available by the EMCDDA’s Reitox network (1) in a 2012 data 
collection exercise comes from isolated studies using various 
methodologies, and the results are not readily comparable. 
For example, a study conducted in an inner-city maternity 
hospital in Dublin, Irelandn found that 4 % of antenatal and 
6 % of postnatal women tested positive for drug metabolites. 
The proportion of urine samples that tested positive for drug 
metabolites was higher among women admitted for labour 
than among women attending scheduled antenatal visits. One 
reason for this may be that women who use drugs are less 
likely to receive antenatal care than women who are drug free.
In a recent study, also using biological specimens, hair 
analysis showed that 16 % of women giving birth in a hospital 
in Ibiza, Spain, had used some type of illicit drug during the 
third trimester of their pregnancy (Friguls et al., 2012), 
although only 2 % of women reported drug use during their 
pregnancy. In Latvia, women reported drug use in 0.2 % of live 
births and 0.8 % of stillbirths. In this country, antenatal care is 
received before the twelfth week of pregnancy by 90 % of 
expectant women in the general population, compared with 
70 % of those who had ever used drugs (EMCDDA, 2012). The 
National Registry of Mothers at Childbirth in the Czech 
(1) Reitox is the European information network on drugs and drug addiction.
TABLE 1
Health harms associated with substance use during pregnancy
Alcohol Tobacco Cannabis Amphetamines Cocaine Opioids
Low birth weight + + + + +
Miscarriage + + + + +
Perinatal mortality + + + (1)
Developmental problems in childhood + + +
Foetal morbidity + + + +
Premature birth + + +
Decreased foetal growth +
Impaired intrauterine growth + +
Neonatal withdrawal symptoms + +
Premature rupture of membranes, placental abruption + +
Preterm delivery +
Respiratory depression +
(1) Related to withdrawal.
NB:  The effect of these drugs may be confounded by polydrug use and/or other health and lifestyle factors associated with drug use.
Source:  A summary of the health harms of drugs, The Centre for Public Health, Faculty of Health & Applied Social Science, Liverpool John Moores University, on 
behalf of the Department of Health and National Treatment Agency for Substance Misuse (2011).
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Untreated opiate dependence in pregnant women is 
associated with many environmental and medical factors that 
contribute to poor maternal and child outcomes. Illicit opioid 
consumption is associated with a sixfold increase in obstetric 
complications such as low birth weight, toxaemia, third 
trimester bleeding, malpresentation, puerperal morbidity (2), 
foetal distress and meconium aspiration. Neonatal 
complications include narcotic withdrawal, postnatal growth 
deficiency, microcephaly, neurobehavioural problems, 
increase in neonatal mortality and a 74-fold increase in 
sudden infant death syndrome (Dattel, 1990; Fajemirokun-
Odudeyi et al., 2006; Ludlow et al., 2004). Neonates born to 
mothers chronically abusing illicit opioids or provided with 
maternal medication-assisted treatment, such as methadone 
or buprenorphine, are frequently born with a passive 
dependency to those specific agents. Intrauterine exposition 
to all of the commonly used opioids, including heroin and 
methadone, but also prescription drugs (OxyContin, Percodan, 
Vicodin, Percocet and Dilaudid), sedative hypnotics such as 
benzodiazepines (e.g. Diazepam) and barbiturates can 
produce neonatal abstinence syndrome (NAS) after disruption 
of the trans-placental passage of drugs at birth. NAS is 
characterised by signs and symptoms of the central nervous 
system, hyperirritability, gastrointestinal dysfunction and 
respiratory and autonomic nervous system symptoms 
(Kaltenbach et al., 1998). However, with the current medical 
knowledge NAS is an easily treatable condition and no infant 
mortality should occur as a result of NAS. 
It is important to note that, contrary to alcohol, 
benzodiazepines and nicotine, opioids do not have teratogenic 
potential (3). Thus, special attention needs to be paid to 
dependence and abuse of legal substances and prescription 
drugs that can have severe consequences for the foetus and 
newborn, such as foetal developmental disorders or sudden 
infant death syndrome (Fetal Alcohol Spectrum Disorders 
Center for Excellence, 2013; McDonnell-Naughton et al., 
2012).
(2) This refers to any illness occurring in the 10 days postpartum.
(3) This means the potential to cause malformations to an embryo or a foetus.
I Description of the interventions
The primary goal of treatment for opioid dependence in 
pregnant women is stabilisation of the patient, in order to 
avoid the permanent fluctuation of plasma levels and related 
foetal consequences, such as foetal distress and preterm 
birth. Psychosocially assisted opioid substitution treatment 
(OST) is the first-line treatment for opioid dependence in 
pregnant women. Each dimension of this multicomponent 
intervention plays a different role. For example, although many 
women want to cease using opioids when they find out they 
are pregnant, they should be encouraged to start or, if this is 
already the case, remain in OST. This is because severe opioid 
withdrawal symptoms resulting from the abrupt interruption of 
opioids can lead to abortion in the first trimester of pregnancy 
or premature labour in the third trimester. Furthermore, a 
possible relapse to heroin use can result in obstetric 
problems.
Since the early 1970s, OST with methadone has been the 
standard treatment for opioid-dependent pregnant women. 
More recently, buprenorphine has been administered to this 
group for OST. Placental transfer of buprenorphine may be 
lower than methadone, reducing foetal exposure and the 
development of NAS (Rayburn and Bogenschutz, 2004). 
Promotion of compliance can be supported in a number of 
ways. Behavioural change techniques play a prominent role 
here. 
In order to guarantee the effectiveness of cognitive 
behavioural interventions, treatment fidelity is important. 
Using standardised, manual-based interventions is an 
important tool here. The main approaches are based on 
motivational interviewing and motivational enhancement 
therapy (see box on page 4).
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Studies conducted between 1988 and 1998 were performed 
in treatment centres offering methadone and comprehensive 
services, including obstetric, health and psychiatric care and 
individual, group and family therapy. Consequently, it is 
difficult to evaluate the results of these studies in order to 
distinguish the benefits of methadone in isolation from social 
measures and obstetric care (Wang, 1999).
The available clinical literature suggests that buprenorphine 
maintenance is associated with reduced maternal illicit opiate 
use and foetal exposure, enhanced compliance with obstetric 
care, and improved neonatal outcomes, such as increased 
birth weight (Johnson et al., 2003; Lejeune et al., 2006).
As already mentioned, pregnancy has been considered a 
‘window of opportunity’ for drug treatment intervention (Daley 
et al., 1998). Maternal concern for the baby has been thought 
of as a motivator to seek treatment. Although qualitative 
studies have documented maternal motivation (Dakof et al., 
2003; Murphy et al., 1999), they have also described the many 
structural and social barriers to both receiving and remaining 
in treatment (Boyd et al., 1999; Murphy et al., 1999).
I How the interventions work
Methadone maintenance given during pregnancy reduces 
maternal illicit opiate use and foetal exposure, enhances 
compliance with obstetric care, and is associated with improved 
neonatal outcomes, such as increased birth weight 
(Fajemirokun-Odudeyi et al., 2006; Sutter et al., 2014). 
Additional benefits include a potential reduction in behaviours 
related to drug-seeking (for example, prostitution as a means to 
raise money for drugs). This reduction may decrease the 
woman’s risk of acquiring sexually transmitted diseases such as 
human immunodeficiency virus (HIV) and hepatitis. For all these 
reasons, methadone treatment has become the ‘gold standard’ 
for the management of pregnant heroin users (NIH, 1998), and 
many national and international guidelines (UK: Department of 
Health (England) and the devolved administrations 2007; USA: 
CSAT, 2005; Australia: Dunlop et al., 2003; and WHO, 2009) 
support the use of methadone during pregnancy (4).
(4)  An inventory of national treatment guidelines and international guidelines is 
available on the EMCDDA’s Best practice portal, at emcdda.europa.eu/
best-practice/standards/treatment
Contingency management (CM): the premise behind CM is 
to systematically use reinforcement techniques to modify 
behaviour in a positive and supportive manner. It has been 
used in the treatment of substance abuse since the 1970s 
(Sitzer and Nancy, 2006). The most common form of CM has 
been the use of monetary vouchers, although prize reinforcers 
have been used as well. CM was first demonstrated to be 
efficacious in both treatment retention and substance 
abstinence in cocaine-dependent individuals (Higgins et al., 
1991), but has subsequently been studied in relation to 
opioids, marijuana, cigarettes, alcohol, benzodiazepines and 
multiple drugs. Recently it has been used in populations of 
pregnant, illicit-drug-dependent women.
Cognitive behavioural therapy (CBT) focuses on altering 
the beliefs that contribute to substance use and providing 
training in coping and skills development (Galanter et al., 
2007). Cognitive strategies (e.g. identifying distorted 
thinking patterns) are typically combined with behavioural 
strategies (e.g. coping with craving to use, communication, 
problem solving, substance refusal skill training) (Waldron 
and Turner, 2008). The Social Behaviour and Network 
Therapy approach uses a range of cognitive and behavioural 
strategies to build social networks supportive of change 
involving the client and other network members (family and 
friends) (UKATT research team, 2001).
Opioid substitution treatment (OST): Also called 
‘substitution therapy’, ‘agonist pharmacotherapy’, ‘agonist 
replacement therapy’ or ‘agonist-assisted therapy’, OST is 
defined as the administration under medical supervision of 
a prescribed psychoactive substance that is 
pharmacologically related to the one producing 
dependence to patients with substance dependence, for 
achieving defined treatment aims. Substitution therapy is 
widely used in the management of nicotine (‘nicotine 
replacement therapy’) and opioid dependence.
Motivational interviewing (MI) and motivational 
enhancement therapy (MET): MI was initially developed for 
treating problem drinkers (Miller et al., 2003). It is a directive, 
client-centred counselling style for eliciting behaviour 
change by helping clients explore and resolve the 
ambivalence surrounding their substance use (Rollnick and 
Miller, 1995). It draws from the trans-theoretical model of 
change (DiClemente and Prochaska, 1998) in order to 
improve treatment readiness and retention. In the 
motivational approach (MI, MET), rather than confront the 
patient’s resistance to abstinence in a direct, possibly 
aggressive, manner, the therapist ‘rolls with resistance’. At 
the same time, he or she tries to help the patient develop 
more self-motivation to stop using via specified techniques 
(Woody, 2003).
The different strategies for treating opioid dependence in pregnancy reviewed in this paper
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substances (licit or illicit) and side effects for the pregnant 
woman/mother. The wellbeing of the child was measured as 
health status (birth weight, Apgar (5) score), NAS, prenatal and 
neonatal mortality and any other side effects for the child.
I Search strategy
In order to identify all of the studies falling within our inclusion 
criteria, we performed structured web-based searches using a 
combination of relevant keywords. These search strategies 
were adapted to query the specialised databases available, 
namely the Cochrane Central Register of Controlled Trials 
(CENTRAL) Issue 3, April 2013, and in particular the Cochrane 
Drugs and Alcohol Group (CDAG) Specialized Register — an 
inventory of studies included in the systematic reviews of 
evidence; PubMed, the platform of the American National 
Library of Medicine, also called MEDLINE (1966 to October 
2013); and EMBASE — a medical database containing 
information on drugs and diseases from pre-clinical studies to 
searches on critical toxicological information (Elsevier, 
EMBASE.com, 1974 to October 2013). Two other databases, 
namely the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL including nursing and allied health 
journals, 1982 to October 2013) and the Web of Science, were 
also consulted. For details of the search strategies for all 
databases, see Annex 2.
Searching other resources
In addition to the web-based searches, we checked our results 
against the reference lists of all relevant papers to identify 
further studies; some of the main electronic sources of 
ongoing trials (National Research Register, meta-Register of 
Controlled Trials; Clinical Trials.gov, Agenzia Italiana del 
Farmaco); conference proceedings likely to contain trials 
relevant to the review (College on Problems of Drug 
Dependence); national focal points for drug research (e.g. 
National Institute of Drug Abuse, National Drug and Alcohol 
Research Centre); and authors of included studies and 
experts in the field in various countries were contacted to find 
out if they knew of any other published or unpublished 
controlled trials. There were no language restrictions at search 
strategy level. If an interesting paper was found in a language 
the screening authors did not read, the paper’s author(s) was/
were contacted for translation.
I Data collection and analysis
Two authors independently screened the titles and abstracts 
of studies obtained by the search strategy. Each potentially 
(5) Activity, pulse, grimace, appearance and respiration.
I Why this review?
Systematic reviews of evidence are available for all the 
substitution treatment and psychosocial approaches to treat 
opioid dependence but only a few of them include studies on 
pregnant women. Furthermore, recent studies have enlarged 
the treatment options for pregnant opioid users. Therefore, an 
overview of the effectiveness of the available interventions is 
needed.
The objective of the present overview is to assess the 
effectiveness of any OST, either alone or in combination with 
psychosocial interventions, for promoting the retention of 
pregnant women in treatment and reducing illicit substance 
use and for improving child health status and reducing 
neonatal mortality.
I Methods
In order to select the studies for inclusion in this review, we set 
the following criteria. We decided to search and include all the 
experimental or quasi-experimental studies involving the 
treatment of opioid dependence for pregnant women. As the 
focus was pregnancy, we excluded any studies that were 
initiated postpartum. Participants in the studies included 
needed to have a diagnosis of opioid dependence (in 
agreement with the standards set by the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition; DSM-
IV) but no criteria were set for gestational age or existing 
comorbidity.
In terms of treatment, we included studies comparing any 
type of pharmacological intervention alone or in combination 
with any type of psychosocial intervention. These treatments 
had to be compared with no intervention or psychosocial 
interventions only. 
The primary outcomes were considered separately for the 
women and the newborn babies concerned. 
Measures of treatment success for the woman were 
considered as the number of women who remained in 
treatment for the whole time planned; evidence of use of illicit 
substances during and/or after the conclusion of the 
treatment/birth of the child. On the obstetric outcomes, the 
measures considered were third trimester bleeding, foetal 
distress and meconium aspiration, caesarean section, 
non-normal presentation, medical complications at delivery, 
breastfeeding following obstetric delivery and puerperal 
morbidity.
Secondary outcomes considered relevant for the pregnant 
woman/mother were nicotine consumption, use of other 
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relevant study located in the search was obtained as full text 
and assessed for inclusion independently by the two authors; 
where disagreements occurred, a third author was consulted. 
Data were extracted independently by the two authors. Any 
disagreements were discussed and resolved by consensus.
Assessment of the risk of bias
The quality of studies must be assessed in order to reduce the 
risk of distorted results due to bias. The risk of bias 
assessment for randomised controlled trials (RCTs) and 
controlled clinical trials (CCTs) in this review was performed 
using the criteria recommended by the Cochrane handbook 
(Higgins et al., 2011). The recommended approach for 
assessing risk of bias in studies included in the Cochrane 
handbook is a two-part tool, addressing seven specific 
domains, namely sequence generation and allocation 
concealment (selection bias); blinding of participants and 
providers (performance bias); blinding of outcome assessor 
(detection bias); incomplete outcome data (attrition bias); 
selective outcome reporting (reporting bias); and other source 
of bias. The first part of the tool involves describing what was 
reported to have happened in the study. The second part of 
the tool involves assigning a judgement relating to the risk of 
bias for that entry (low, high or unclear). To make these 
judgements, we used the criteria indicated by the handbook 
adapted to the addiction field (see Annex 3 for details).
The domains of sequence generation and allocation 
concealment (avoidance of selection bias) were addressed in 
the tool by a single entry for each study. Blinding of 
participants to treatment, blinding of personnel and outcome 
assessors to the allocation of patients (avoidance of 
performance bias and detection bias) were considered 
separately for objective outcomes (e.g. dropout, use of 
substance of abuse measured by urine analysis, subjects 
relapsed at the end of follow-up, subjects engaged in further 
treatments) and subjective outcomes (e.g. duration and 
severity of signs and symptoms of withdrawal, patient 
self-reported use of substance and side effects). Data were 
extracted independently by two authors. Any disagreement 
was resolved by discussion.
The main objective of epidemiological research is to find 
explanations to the manifestation of diseases in the 
population. Bias is a false result influenced by 
uncontrolled factors. A typical example of bias is an 
unwanted selection of the population studied so that the 
sample does not adequately represent the target 
population. Bias has been defined as ‘incorrect 
assessment of the association between an exposure and 
an effect in the target population’ (Delgado-Rodríguez 
and Llorca, 2004). The quality of studies is highly linked 
to the reduction of possible bias. There are many known 
types of bias, including selection bias, the risk of 
selecting the sample for uncontrolled characteristics 
(Delgado-Rodríguez and Llorca, 2004); attrition bias, 
one type of selection bias which is related to the number 
of patients that leave a study before the final 
assessment; indication bias, which emerges in RCTs 
when patients, instead of being assigned to treatment 
randomly, are assigned on the basis of some 
characteristics, for example a higher susceptibility to 
some disease; and assessment bias or detection bias, 
when the professionals assessing the results of an 
intervention are influenced by their knowledge of the 
interventions provided. A typical example is a nurse who 
measures body temperature more often or more 
accurately in the patients given placebo than in those 
given the active substance. 
Why are some studies defined as ‘blinded’?
Blinding refers to all of the strategies put in place to 
prevent knowledge of the intervention influencing 
behaviour (of patients or clinicians, carers or outcome 
assessors), hence leading to biased results 
(performance bias). In an RCT, patients are often blinded 
to the intervention so that they cannot over-report or 
under-report some symptoms. The same strategy applies 
to assessors. The term ‘double blind’ describes a 
situation in which neither the patient nor the assessor of 
the outcome (for example, the professional asking 
questions) aware of the treatment provided to the 
specific patient.
What is bias?
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this heterogeneity in the meta-analysis (the pooled estimate 
of study results), some specific statistical tests were used. The 
test that was used in this overview to measure and control the 
heterogeneity was the I2 statistic and chi-squared test for 
heterogeneity (Higgins et al., 2003). A heterogeneity test 
higher than 50 % indicates that the results of the analysis 
must be interpreted with caution. 
Grading of evidence
In order to classify the quality of the evidence, the Grading of 
Recommendation, Assessment, Development, and Evaluation 
Working Group (GRADE) developed a system (Guyatt et al., 
2008; Schünemann et al., 2003) which takes into account 
issues related not only to internal validity — for example the 
risks of bias — but also to external validity, or generalisability 
of results, such as directness of results (6). The overall quality 
of the evidence for the primary outcome was assessed using 
the GRADE system.
Table 4 presents the main findings of the review and key 
information concerning the quality of evidence, the magnitude 
of effect of the interventions examined, and the sum of 
available data on the main outcomes. 
Data synthesis
The outcome measures from the individual trials were 
combined through meta-analysis where possible 
(comparability of intervention and outcomes between trials) 
using the fixed effects model (7), as the studies were expected 
to be similar in terms of types of participants, settings and 
treatments administered. 
Sensitivity analysis for risk of bias
It is possible to assess the risk of bias in the included studies 
(see box ‘What is bias? on page 6) before conducting the 
meta-analysis. The method used in this type of review helps 
visualise studies that are outliers in respect of several 
outcomes. In order to include an assessment of the risk of bias 
in the review process, we can start by plotting the intervention 
effect estimates against the assessment of risk of bias. If we 
find significant associations between the measures of effect 
and risk of bias, this would exclude from the analysis studies 
with a high risk of bias. The items considered in the sensitivity 
analysis would be random sequence generation, allocation 
(6)  More details about the GRADE system can be found at gradeworkinggroup.
org/
(7)  The fixed effects model is a statistical technique that is used when studies are 
expected to be sufficiently similar to be pooled together without the need to 
balance for heterogeneity.
Measures of treatment effect
Measures of effects were calculated separately for two main 
types of outcomes. Dichotomous outcomes include those that 
can have only two results (the typical one being mortality, as a 
person can be only dead or alive). These outcomes were 
analysed calculating the risk ratio (RR) for each trial. The RR is 
used to compare the risk in the two different groups of people, 
i.e. treated and control groups, in order to ascertain whether 
belonging to one group or another increases or decreases the 
risk of developing certain outcomes. As a general rule, a RR 
that is lower than 1 indicates a reduction in risk while a RR 
exceeding 1 indicates an increased risk. 
Confidence intervals are a measure of the uncertainty of a 
result that indicates the minimum and the maximum the result 
can assume for the effect of chance. Confidence intervals 
include two measures: the lower and the upper. As a rule of 
thumb in interpretation, a confidence interval including 1 is 
considered not statistically significant because it includes the 
case in which the RRs in the two groups compared is equal 
and the intervention tested has no effect.
Continuous outcomes can assume many different measures 
(for example, blood pressure). These outcomes were analysed 
calculating the mean difference (MD) or the standardised 
mean difference with confidence intervals of 95 %.
Furthermore, when data on the number of participants using a 
substance (dichotomous outcome) were reported, we used 
these data instead of the data presented as the number of 
positive urine tests over the total number of tests (continuous 
measure) in the experimental and control group, as a measure 
of substance abuse. This is because using tests instead of the 
participants as the unit of analysis violates the hypothesis of 
independence among observations. In fact, multiple tests on 
the same patients cannot be considered independent 
observations. Nevertheless, if only continuous measures were 
available, we used them.
Assessment of heterogeneity
Overviews such as the present one typically include several 
studies which, by definition, differ: they have been conducted 
in various places and times and include several populations 
(they are heterogeneous). The difference can be clinical (i.e. 
related to the interventions and the patients) or statistical. 
Statistical heterogeneity occurs when the variation is higher 
than expected for the mere effect of chance. While clinical 
heterogeneity brings important information (for example, it 
says that one intervention is more effective in patients with 
some characteristics than in others), statistical heterogeneity 
can be misleading. For this reason, techniques exist to 
minimise the effect of the heterogeneity. In order to consider 
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I Included studies
Ten studies involving 728 participants satisfied the criteria for 
inclusion (Carroll et al., 1995; Fischer et al., 1999; Fischer et 
al., 2006; Haug et al., 2004; Jones et al., 2005; Jones et al., 
2011; MOTHER Study; O’Neill et al., 1996; Silverman et al., 
2001; Tuten et al., 2012). 
Trials ranged from 2 to 36 weeks, with a mean duration of 18 
weeks. The countries covered by the trials were the United 
States (six), Austria (two), Australia (one) and Austria, Canada 
and the United States (one). The last was the MOTHER Study 
— a multicentre international study. Four trials, with a total of 
271 participants, assessed the effectiveness of agonist 
maintenance treatments. Three of them compared methadone 
(dose between 20 and 140 mg/day) with buprenorphine (dose 
between 2 and 32 mg /day) (Fischer et al., 2006; Jones et al., 
2005; MOTHER Study) and one compared methadone (mean 
dose at delivery 53.48 mg) with slow-release oral morphine 
(SROM; mean dose at delivery 300.43 mg) (Fischer et al., 
1999). Six studies involving 457 participants (Carroll et al., 
1995; Haug et al., 2004; Jones et al., 2011; O’Neill et al., 1996; 
Silverman et al., 2001; Tuten et al., 2012) assessed the 
effectiveness of psychosocial interventions combined with 
agonist maintenance treatment.
Nine studies were conducted in outpatient settings and one in 
an inpatient setting. Four studies were conducted in both 
settings. The psychosocial interventions considered in the 
studies were CM — three studies (Carroll et al., 1995, 
Silverman et al., 2001, Tuten et al., 2012); MET — one study 
(Haug et al., 2004); Cognitive Behavioral Relapse Prevention 
Therapy — one study (O’Neill et al., 1996); and one therapeutic 
workplace study (Tuten et al., 2012). The six studies that 
assessed the effectiveness of psychosocial interventions 
combined with agonist maintenance treatment were very 
heterogeneous in terms of study objective, types of 
interventions compared, types of outcomes and ways of 
measuring outcomes. A pooled analysis of the results was 
possible only for retention in treatment within each subgroup; 
the other results have been described in a narrative way. 
The total number of participants was 728 opiate-dependent 
pregnant women meeting DSM-IV criteria with a mean age of 
28.9 years and a mean gestational age of 25 weeks. 
For a detailed description of characteristics of included 
studies, see Annex 1.
concealment, blinding of personnel and outcome assessors. 
However, in the present overview it was not possible to 
perform such a sensitivity analysis because of the small 
number of studies included.
I Results
FIGURE 1
Flow chart of the process
I Results of the search
We identified a total of 968 records (Figure 1) but 927 were 
excluded because the title and abstract were not relevant and 
41 articles were retrieved as full text in order to perform a 
more detailed evaluation. Following this evaluation, 20 were 
excluded, leaving 10 studies (21 references) that satisfied all 
the criteria for inclusion. We did not find any unpublished 
studies. We wrote to the first authors of published studies and 
one replied, who confirmed that, to his knowledge, there were 
no unpublished trials.
968 records after duplicates removed
968 records 
screened
41 full-text articles 
assessed for 
eligibility
21 articles (10 
studies) included
927 records 
excluded based on 
title and abstract
20 full-text articles 
excluded, with 
reasons
Records identified through 
database searching (CDAG 
Register: 115; PubMED: 672; 
CENTRAL: 84; EMBASE: 226; 
CINAHL: 110; WOS: 178)
0 additional records identified 
through other sources
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As shown in Table 2 above, random sequence generation 
(selection bias) exists in three studies (Jones et al., 2005; 
Jones et al., 2011; Silverman et al., 2001). These used a 
random sequence generation method at low risk of selection 
bias. All other studies were judged at unclear risk of bias. 
Allocation concealment (selection bias) was at low risk of bias 
in three studies (Fischer et al., 2006; Jones et al., 2005; 
MOTHER Study) and unclear risk in all the others. Concerning 
the blinding of participants and/or personnel (performance 
bias) and outcome assessor (assessment or detection bias): 
for subjective outcomes, three studies (Fischer et al., 2006; 
Jones et al., 2005; MOTHER Study) were double-blind judged 
at low risk; seven studies were judged at high risk of 
performance bias, one (Fischer et al., 1999) because it was an 
open study and the other six (Carroll et al., 1995; Haug et al., 
2004; Jones et al., 2011; O’Neill et al., 1996; Silverman et al., 
2001; Tuten et al., 2012) because blinding of participants and 
personnel was not possible for the types of intervention 
compared. For objective outcomes, all studies were judged at 
low risk of performance and detection bias. For incomplete 
outcome data (attrition bias), only one study had no attrition. 
Four studies were judged at low risk of bias (Carroll et al., 
1995; Fischer et al., 1999; Jones et al., 2011; O’Neill et al., 
1996). The other studies were judged at high risk of attrition 
bias because the attrition rate was high and not balanced 
between groups. 
I Effects of interventions
Mothers
1. Retention in treatment
The studies showed that both patients treated with 
methadone and those given SROM remained in treatment as 
planned. Adding cognitive behavioural interventions and CM 
to treatment was found to potentially improve retention in 
treatment. 
2. Use of substances
Methadone and SROM helped patients to abstain from using 
illicit substances. The addition of CM or cognitive behavioural 
approaches did not change the results in two studies out of 
three (but some results were apparent at 9-month follow-up, 
when the control group increased use). Other illicit substances 
were found in the urine analysis and the only relevant result 
was the effect of CM on reducing cocaine use. No significant 
differences were observed among groups for the number of 
cigarettes smoked per day. 
3. Obstetrical outcomes
3.1. Premature delivery
In two out of three studies there were more premature 
deliveries in the methadone group than in the buprenorphine 
group, and in the morphine group the mean week of delivery 
was lower. However, no statistically significant differences 
were reported in any of the studies. The addition of CM 
seemed to improve the completion of gestation.
3.2. Caesarean section
In one out of three studies, the percentage of caesareans was 
lower in the patients in the buprenorphine group. No 
differences were reported in the remaining patients.
3.3. Foetal presentation and puerperal morbidity
In one of the studies, there were more newborn babies with 
abnormal presentation (i.e. not head first) in methadone- 
TABLE 2
Methodological quality of included studies
Level of risk
Random sequence generation 
(selection bias)
Allocation concealment 
(indication bias)
Blinding of participants and 
outcome assessors 
(performance and assessment 
or detection bias)
Incomplete data 
outcomes (attrition bias)
Low risk of bias Jones et al., 2005; Jones et al., 
2011; Silverman et al., 2001
Fischer et al., 2006; Jones et 
al., 2005; MOTHER Study
Fischer et al., 2006; Jones et al., 
2005; MOTHER Study
Carroll et al., 1995; Fischer 
et al., 1999; Jones et al., 
2011; O’Neill et al., 1996
Description unclear Carroll et al., 1995; Fischer et 
al., 1999; Fischer et al., 2006; 
Haug et al., 2004; MOTHER 
Study; O’Neill et al., 1996; 
Tuten et al., 2012
Carroll et al., 1995; Fischer et 
al., 1999; Haug et al., 2004; 
Jones et al., 2011; O’Neill et 
al., 1996; Silverman et al., 
2001; Tuten et al., 2012
Any risk of bias Carroll et al., 1995; Fischer et 
al., 1999; Haug et al., 2004; 
Jones et al., 2011; O’Neill et al., 
1996; Silverman et al., 2001; 
Tuten et al., 2012
Fischer et al., 2006; Haug 
et al., 2004; Jones et al., 
2005; MOTHER Study; 
Silverman et al., 2001; 
Tuten et al., 2012 
Note: All the studies were randomised controlled trails.
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morphine needed to treat NAS was lower in the buprenorphine 
group, the mean stay in hospital for the treatment of NAS was 
lower in the buprenorphine group. 
When comparing methadone with SROM, there were no 
differences in the length of time the infants remained in 
hospital for detoxification. In one study, in the methadone 
group there were two fatalities. No prenatal or neonatal deaths 
occurred in the methadone versus SROM study.
3. Apgar score 
The Apgar score is a clinical test for newborn babies at one 
and five minutes after birth. The one-minute score determines 
how well the baby tolerated the birthing process. The five-
minute score tells the doctor how well the baby is doing 
outside the mother’s womb (MedlinePlus, accessed July 
2014).
Three studies reported the Apgar score at five minutes after 
birth as showing no differences among the groups. 
4. Side effects for the baby
In one study there were more side effects in the babies born to 
mothers treated with methadone (statistically significant). 
Conversely, the non-serious side effects were higher in the 
buprenorphine-treated group (measure was non-statistically 
significant).
rather than in buprenorphine-treated mothers. Nevertheless, 
the difference was considered not statistically significant. 
None of the mothers participating in the studies had any 
illness in the 10 days after giving birth.
3.4. Side effects for the mothers
The side effects were not statistically significant and more 
frequent in methadone- than in buprenorphine-treated 
women.
Newborn babies
1. Birth weight 
In one of the studies, the newborns of mothers treated with 
buprenorphine had higher weight at birth, and in another 
study, the babies of mothers provided with CM in addition to 
usual care had a higher birth weight.
2. Neonatal abstinence syndrome
In three studies, the RR for the baby having NAS was not 
statistically significant and slightly higher in the 
buprenorphine- than in the methadone-treated group. The 
score for NAS peak over all observation days was lower in the 
buprenorphine group in one study and lower in the methadone 
group in another. The mean duration of treatment for NAS was 
not different across the groups and the total amount of 
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l. 
(2
0
0
4
) 
re
p
o
rt
e
d
 t
h
at
 r
e
su
lt
s 
o
f o
n
e
-w
ay
 
an
al
ys
is
 o
f c
o
va
ri
an
ce
 d
id
 n
o
t s
h
o
w
 a
 s
ig
n
ifi
ca
n
t 
d
iff
e
re
n
ce
 b
et
w
e
e
n
 t
re
at
m
e
n
t c
o
n
d
it
io
n
s 
o
n
 
se
lf-
re
p
o
rt
e
d
 c
ig
ar
et
te
 u
se
 p
e
r 
d
ay
, C
O
 o
r 
co
ti
n
in
e
.
=
H
au
g 
et
 a
l.,
 2
0
0
4
U
se
 o
f 
ot
h
er
 s
u
b
st
an
ce
(s
) 
of
 a
b
u
se
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
Jo
n
e
s 
et
 a
l. 
(2
0
0
5
) 
re
p
o
rt
e
d
 t
h
e 
p
e
rc
e
n
ta
g
e 
o
f 
p
o
si
ti
ve
 u
ri
n
e 
te
st
s 
fo
r 
e
a
ch
 s
u
b
st
an
ce
 d
u
ri
n
g 
th
e 
st
u
d
y 
p
e
ri
o
d
 f
o
r 
th
e 
m
et
h
a
d
o
n
e 
an
d
 b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
s 
re
sp
e
ct
iv
e
ly
 a
s 
fo
llo
w
s:
 c
o
ca
in
e:
 1
5
.6
 %
 a
n
d
 
1
6
.7
 %
; b
e
n
zo
d
ia
ze
p
in
e
s:
 0
.4
 %
 a
n
d
 2
.5
 %
; 
am
p
h
et
am
in
e:
 0
 %
 a
n
d
 0
 %
; m
ar
iju
an
a 
7.
5
 %
 a
n
d
 
0
 %
. F
is
ch
e
r 
et
 a
l. 
(2
0
0
6
) 
re
p
o
rt
e
d
 t
h
e 
m
e
d
ia
n
 
n
u
m
b
e
r 
o
f u
ri
n
e 
sa
m
p
le
s 
p
o
si
ti
ve
 f
o
r 
m
et
h
a
d
o
n
e 
an
d
 b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
s 
re
sp
e
ct
iv
e
ly
 a
s 
fo
llo
w
s:
 
co
ca
in
e:
 0
.0
0
, 0
.0
0
; b
e
n
zo
d
ia
ze
p
in
e
s:
 7
.8
2
 a
n
d
 5
.3
6
. 
N
o
 d
at
a 
ar
e 
re
p
o
rt
e
d
 in
 t
h
e 
M
O
T
H
E
R
 S
tu
d
y
?
Jo
n
e
s 
et
 a
l.,
 2
0
0
5
; 
F
is
ch
e
r 
et
 a
l.,
 2
0
0
6
M
et
h
a
d
o
n
e 
ve
rs
u
s 
S
R
O
M
Th
e 
st
u
d
y 
re
p
o
rt
e
d
 t
h
e 
p
e
rc
e
n
ta
g
e 
o
f n
e
g
at
iv
e 
u
ri
n
e 
to
xi
co
lo
g
y 
d
u
ri
n
g 
e
a
ch
 w
e
e
k 
o
f t
re
at
m
e
n
t f
o
r 
m
et
h
a
d
o
n
e 
an
d
 s
lo
w
-r
e
le
as
e 
m
o
rp
h
in
e 
o
n
ly
 in
 a
 
g
ra
p
h
: t
h
e 
m
e
an
 p
e
rc
e
n
ta
g
e
s 
fo
r 
th
e 
w
h
o
le
 s
tu
d
y 
p
e
ri
o
d
 w
e
re
 a
b
o
u
t 9
5
 %
 a
n
d
 9
0
 %
 r
e
sp
e
ct
iv
e
ly
 f
o
r 
co
ca
in
e 
an
d
 5
4
 %
 a
n
d
 8
9
 %
 f
o
r 
b
e
n
zo
d
ia
ze
p
in
e
s.
?
F
is
ch
e
r 
et
 a
l.,
 1
9
9
9
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O
u
tc
om
es
In
te
rv
en
ti
on
s
E
ff
ec
ts
Q
u
ic
k 
g
u
id
e
R
ef
er
en
ce
s
A
d
d
it
io
n
al
 in
fo
rm
at
io
n
C
M
 a
p
p
ro
a
ch
 p
lu
s 
u
su
al
 
ca
re
 v
e
rs
u
s 
u
su
al
 c
ar
e
C
ar
ro
ll 
et
 a
l. 
(1
9
9
5
) 
re
p
o
rt
e
d
 t
h
at
 t
h
e
re
 w
e
re
 n
o
 
si
g
n
ifi
ca
n
t d
iff
e
re
n
ce
s 
b
et
w
e
e
n
 t
h
e 
e
n
h
an
ce
d
 a
n
d
 
st
an
d
ar
d
 t
re
at
m
e
n
t g
ro
u
p
s 
w
it
h
 r
e
sp
e
ct
 t
o
 
p
e
rc
e
n
ta
g
e 
o
f m
at
e
rn
al
 u
ri
n
e 
to
xi
co
lo
g
y 
sc
re
e
n
s 
th
at
 w
e
re
 p
o
si
ti
ve
 f
o
r 
co
ca
in
e 
o
r 
an
y 
o
th
e
r 
d
ru
g
, b
u
t 
d
at
a 
ar
e 
n
o
t s
h
o
w
n
.
In
 J
o
n
e
s 
et
 a
l. 
(2
01
1
) 
th
er
e 
w
as
 a
 s
ig
n
ifi
ca
n
t e
ff
e
ct
 o
f 
th
e 
in
ce
n
ti
ve
s 
o
n
 t
h
e 
ra
te
 o
f c
o
ca
in
e 
u
se
 (F
 (1
,7
8
)=
 
7.
0
5
, P
<
0
.0
5
); 
as
 s
o
o
n
 a
s 
th
e 
vo
u
ch
er
s 
w
er
e 
n
o
 
lo
n
ge
r 
av
ai
la
b
le
, t
h
e 
ra
te
s 
o
f p
o
si
ti
ve
 u
ri
n
e 
sa
m
p
le
s 
w
er
e 
n
o
 lo
n
ge
r 
d
iff
er
en
t b
et
w
e
en
 t
h
e 
tw
o
 g
ro
u
p
s.
In
 T
u
te
n
 e
t a
l. 
(2
0
1
2
) 
th
e 
n
u
m
b
e
r 
o
f c
o
ca
in
e
-
n
e
g
at
iv
e 
u
ri
n
e 
te
st
s 
w
as
 n
o
t s
ta
ti
st
ic
al
ly
 s
ig
n
ifi
ca
n
tl
y 
d
iff
e
re
n
t i
n
 t
h
e 
co
m
p
ar
is
o
n
 c
o
m
b
in
in
g 
e
sc
al
at
in
g 
an
d
 fi
xe
d
 r
e
in
fo
rc
e
m
e
n
t c
o
n
d
it
io
n
 v
e
su
s 
u
su
al
 c
ar
e 
(F
 (1
, 5
4
.3
)=
 0
.0
1
, P
=
 0
.9
1
), 
as
 w
e
ll 
as
 t
h
e 
lo
n
g
e
st
 
co
n
se
cu
ti
ve
 n
u
m
b
e
r 
o
f n
e
g
at
iv
e 
u
ri
n
e 
te
st
s 
(F
 (1
, 6
0
.2
)=
 1
.0
8
, P
=
0
.3
0
).
=
C
ar
ro
ll 
et
 a
l.,
 1
9
9
5
; 
Jo
n
e
s 
et
 a
l.,
 2
0
11
; 
Tu
te
n
 e
t a
l.,
 2
0
1
2
C
o
g
n
it
iv
e 
b
e
h
av
io
u
ra
l 
ap
p
ro
a
ch
 p
lu
s 
u
su
al
 c
ar
e 
ve
rs
u
s 
u
su
al
 c
ar
e
H
au
g 
et
 a
l. 
(2
0
0
4
) 
re
p
o
rt
e
d
 t
h
at
 n
o
 s
ig
n
ifi
ca
n
t 
d
iff
e
re
n
ce
s 
w
e
re
 f
o
u
n
d
 b
et
w
e
e
n
 t
re
at
m
e
n
t 
co
n
d
it
io
n
s 
fo
r 
p
o
si
ti
ve
 u
ri
n
e 
te
st
s 
fo
r 
co
ca
in
e
.
=
H
au
g 
et
 a
l.,
 2
0
0
4
O
b
st
et
ri
c 
ou
tc
om
es
 
p
re
te
rm
 d
el
iv
er
y
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
In
 F
is
ch
e
r 
et
 a
l. 
(2
0
0
6
), 
th
re
e 
b
ab
ie
s 
w
e
re
 d
e
liv
e
re
d
 
p
re
m
at
u
re
ly
 in
 t
h
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
 a
n
d
 t
w
o
 in
 t
h
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
. I
n
 t
h
e 
M
O
T
H
E
R
 S
tu
d
y 
1
9
 %
 o
f 
d
e
liv
e
ri
e
s 
w
e
re
 p
re
te
rm
 in
 t
h
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
 
an
d
 7
 %
 in
 t
h
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
. Th
e 
d
iff
e
re
n
ce
 
w
as
 n
o
t s
ta
ti
st
ic
al
ly
 s
ig
n
ifi
ca
n
t.
=
F
is
ch
e
r 
et
 a
l.,
 2
0
0
6
; 
M
O
T
H
E
R
 S
tu
d
y
M
et
h
a
d
o
n
e 
ve
rs
u
s 
S
R
O
M
O
n
e 
fe
m
al
e 
d
e
liv
e
re
d
 a
t 3
1
 w
e
e
ks
 d
u
e 
to
 e
ar
ly
 
am
n
io
ti
c 
ru
p
tu
re
, b
u
t i
t i
s 
n
o
t r
e
p
o
rt
e
d
 w
h
ic
h
 g
ro
u
p
 
sh
e 
b
e
lo
n
g
e
d
 t
o
. M
e
an
 w
e
e
k 
o
f d
e
liv
e
ry
 f
o
r 
m
et
h
a
d
o
n
e:
 3
8
.9
2
 (
S
D
 1
.7
4
) 
an
d
 m
o
rp
h
in
e:
 3
7.
7
9
 
(S
D
 2
.5
5
). 
Th
e 
d
iff
e
re
n
ce
 w
as
 n
o
t s
ta
ti
st
ic
al
ly
 
si
g
n
ifi
ca
n
t.
=
F
is
ch
e
r 
et
 a
l.,
 1
9
9
9
C
M
 a
p
p
ro
a
ch
 p
lu
s 
u
su
al
 
ca
re
 v
e
rs
u
s 
u
su
al
 c
ar
e
O
n
ly
 C
ar
ro
ll 
et
 a
l. 
(1
9
9
5
) 
re
p
o
rt
e
d
 o
b
st
et
ri
c 
o
u
tc
o
m
e
s 
an
d
 t
h
e 
o
n
ly
 o
u
tc
o
m
e 
re
p
o
rt
e
d
 w
as
 t
h
e 
m
e
d
ia
n
 t
e
rm
 o
f d
e
liv
e
ry
 (C
M
: 4
0
), 
u
su
al
 c
ar
e 
3
8
. 
?
C
ar
ro
ll 
et
 a
l.,
 1
9
9
5
C
ae
sa
re
an
 s
ec
ti
on
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
In
 J
o
n
e
s 
et
 a
l. 
(2
0
0
5
), 
al
l b
u
t o
n
e 
b
ir
th
 in
 e
ac
h
 g
ro
u
p
 
w
er
e 
va
g
in
al
. I
n
 F
is
ch
er
 e
t a
l. 
(2
0
0
6
), 
tw
o
 w
o
m
en
 
m
ai
n
ta
in
e
d
 o
n
 b
u
p
re
n
o
rp
h
in
e 
d
el
iv
er
e
d
 b
y 
p
la
n
n
e
d
 
ca
e
sa
re
an
 s
e
ct
io
n
 a
t w
e
ek
 4
0
. I
n
 t
h
e 
M
O
T
H
E
R
 S
tu
d
y 
th
er
e 
w
er
e 
3
7
 %
 c
ae
sa
re
an
 s
e
ct
io
n
s 
in
 t
h
e 
m
et
h
ad
o
n
e 
g
ro
u
p
 a
n
d
 2
9
 %
 in
 t
h
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
. Th
e 
d
iff
er
en
ce
 w
as
 n
o
t s
ta
ti
st
ic
al
ly
 s
ig
n
ifi
ca
n
t.
=
Jo
n
e
s 
et
 a
l.,
 2
0
0
5
; 
F
is
ch
e
r 
et
 a
l.,
 2
0
0
6
; 
M
O
T
H
E
R
 S
tu
d
y
M
et
h
a
d
o
n
e 
ve
rs
u
s 
S
R
O
M
2
5
 %
 in
 b
o
th
 g
ro
u
p
s.
=
F
is
ch
e
r 
et
 a
l.,
 1
9
9
9
C
om
p
lic
at
io
n
s 
at
 d
el
iv
er
y
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
In
 F
is
ch
e
r 
et
 a
l. 
(2
0
0
6
) 
o
n
e 
w
o
m
an
 in
 t
h
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
 r
e
q
u
ir
e
d
 v
a
cu
u
m
 e
xt
ra
ct
io
n
 d
u
e 
to
 a
 p
ro
lo
n
g
e
d
 d
e
liv
e
ry
. N
o
 m
e
d
ic
al
 c
o
m
p
lic
at
io
n
s 
o
cc
u
rr
e
d
 in
 J
o
n
e
s 
et
 a
l. 
(2
0
0
5
). 
In
 t
h
e 
M
O
T
H
E
R
 
S
tu
d
y 
th
e
re
 w
e
re
 5
1
 %
 m
e
d
ic
al
 c
o
m
p
lic
at
io
n
s 
at
 
d
e
liv
e
ry
 in
 t
h
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
 a
n
d
 3
1
 %
 in
 t
h
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
 (
P
=
 0
.0
3
).
=
(o
n
e 
st
u
d
y 
+
 
b
u
p
re
-
n
o
rp
h
in
e)
Jo
n
e
s 
et
 a
l.,
 2
0
0
5
; 
F
is
ch
e
r 
et
 a
l.,
 2
0
0
6
; 
M
O
T
H
E
R
 S
tu
d
y
M
et
h
a
d
o
n
e 
ve
rs
u
s 
S
R
O
M
8
.3
 %
 in
 b
o
th
 g
ro
u
p
s.
=
F
is
ch
e
r 
et
 a
l.,
 1
9
9
9
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O
u
tc
om
es
In
te
rv
en
ti
on
s
E
ff
ec
ts
Q
u
ic
k 
g
u
id
e
R
ef
er
en
ce
s
A
d
d
it
io
n
al
 in
fo
rm
at
io
n
M
ec
on
iu
m
 a
sp
ir
at
io
n
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
In
 t
h
e 
M
O
T
H
E
R
 S
tu
d
y,
 t
h
e
re
 w
as
 o
n
e 
ca
se
 o
f 
m
e
co
n
iu
m
 a
sp
ir
at
io
n
 in
 t
h
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
.
=
M
O
T
H
E
R
 S
tu
d
y
F
oe
ta
l p
re
se
n
ta
ti
on
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
In
 J
o
n
e
s 
et
 a
l. 
(2
0
0
5
) 
al
l b
ir
th
s 
w
e
re
 n
o
rm
al
 
p
re
se
n
ta
ti
o
n
s;
 in
 t
h
e 
M
O
T
H
E
R
 S
tu
d
y 
th
e
re
 w
e
re
 
14
 %
 a
b
n
o
rm
al
 f
o
et
al
 p
re
se
n
ta
ti
o
n
s 
in
 t
h
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
 a
n
d
 5
 %
 in
 t
h
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
. A
b
n
o
rm
al
 p
re
se
n
ta
ti
o
n
s 
ar
e 
co
n
si
d
e
re
d
 a
s 
al
l 
n
o
n
-c
e
p
h
al
ic
 (
h
e
a
d
 fi
rs
t)
 f
o
et
al
 p
o
si
ti
o
n
s 
at
 b
ir
th
. 
Th
e 
d
iff
e
re
n
ce
 w
as
 n
o
t s
ta
ti
st
ic
al
ly
 s
ig
n
ifi
ca
n
t.
=
Jo
n
e
s 
et
 a
l.,
 2
0
0
5
; 
M
O
T
H
E
R
 S
tu
d
y
P
u
er
p
er
al
 m
or
b
id
it
y
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
N
o
 c
as
e
s 
o
f p
u
e
rp
e
ra
l m
o
rb
id
it
y 
(a
n
y 
ill
n
e
ss
 
o
cc
u
rr
in
g 
in
 t
h
e 
1
0
 d
ay
s 
p
o
st
p
ar
tu
m
) 
w
e
re
 
o
b
se
rv
e
d
 in
 J
o
n
e
s 
et
 a
l. 
(2
0
0
5
) 
an
d
 in
 t
h
e 
M
O
T
H
E
R
 
S
tu
d
y.
=
Jo
n
e
s 
et
 a
l.,
 2
0
0
5
; 
M
O
T
H
E
R
 S
tu
d
y
S
id
e 
eff
ec
ts
 f
or
 t
h
e 
w
om
an
M
et
h
a
d
o
n
e 
ve
rs
u
s 
b
u
p
re
n
o
rp
h
in
e
N
o
 s
id
e 
e
ff
e
ct
s 
fo
r 
th
e 
m
o
th
e
r 
w
e
re
 r
e
p
o
rt
e
d
 in
 
Jo
n
e
s 
et
 a
l. 
(2
0
0
5
) 
an
d
 F
is
ch
e
r 
et
 a
l. 
(2
0
0
6
). 
In
 t
h
e 
M
O
T
H
E
R
 S
tu
d
y 
th
e
re
 w
e
re
 1
4
/8
9
 (1
6
 %
) 
se
ri
o
u
s 
a
d
ve
rs
e 
e
ve
n
ts
 in
 t
h
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
 a
n
d
 8
/8
6
 
(9
 %
) 
in
 t
h
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
; R
R
: 1
.8
2
 (
9
5
 %
 C
I 
0
.7
2
–
 4
.5
9
).
Th
e
re
 w
e
re
 a
ls
o
 8
3
/8
9
 (
9
3
 %
) 
n
o
n
-s
e
ri
o
u
s 
a
d
ve
rs
e 
e
ve
n
ts
 in
 t
h
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
 a
n
d
 6
6
/8
6
 (
7
7
 %
) 
in
 
th
e 
b
u
p
re
n
o
rp
h
in
e 
g
ro
u
p
; R
R
: 5
.1
0
 (
9
5
 %
 C
I 
0
.6
0
–
 4
3
.6
6
); 
th
e 
re
su
lt
 w
as
 n
o
t s
ta
ti
st
ic
al
ly
 
si
g
n
ifi
ca
n
t.
=
M
O
T
H
E
R
 S
tu
d
y
Th
e 
a
d
ve
rs
e 
e
ve
n
ts
 w
e
re
, 
re
sp
e
ct
iv
e
ly
:
F
o
r 
th
e 
m
et
h
a
d
o
n
e 
g
ro
u
p
: a
b
n
o
rm
al
 
fo
et
al
 h
e
al
th
 (t
h
re
e 
ca
se
s)
, o
n
e 
ca
se
 
o
f c
ar
d
io
va
sc
u
la
r 
sy
m
p
to
m
s,
 o
n
e 
o
f 
g
as
tr
o
in
te
st
in
al
 s
ym
p
to
m
s,
 o
n
e 
o
f 
ill
ic
it
 d
ru
g 
u
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at
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TABLE 4
Methadone compared to buprenorphine for opiate-dependent pregnant women
Outcomes
Illustrative comparative risks (*) (95 % CI)
Relative effect 
(95 % CI)
No of 
participants 
(studies)
Quality of the 
evidence 
(GRADE)
Assumed risk Corresponding risk
Buprenorphine Methadone
Dropout 
Objective 
Follow-up: 15 to 
18 weeks
Study population RR 0.64 
(0.41 to 1.01)
223 (3 studies) +  +  -  -  
Low (1) (2)318 per 1000 204 per 1000 
(134 to 321)
Moderate
326 per 1000 209 per 1000 
(134 to 329)
Use of primary 
substance 
Objective 
Follow-up: 15 to 
18 weeks
Study population RR 1.81 
(0.7 to 4.69)
151 (2 studies) +  +  -  -  
Low (1) (2)75 per 1000 135 per 1000 
(52 to 350)
Moderate
43 per 1000 78 per 1000 
(30 to 202)
Birth weight 
Objective 
Follow-up: mean 
18 weeks
The mean birth weight 
difference ranged 
across control groups 
from 3.53 to 3.09 g
The mean birth weight 
in the intervention 
groups  
was  
224.91 g lower 
(248.46 g to 
201.36 g lower)
150 (2 studies) +  +  -  -  
Low (1) (2) (3) (4)
Apgar score  
Objective: Scale 
from 0 to 10 
Follow-up: mean 
18 weeks
The mean Apgar 
score ranged across 
control groups from 
8.9 to 9.0
The mean Apgar 
score in the 
intervention groups 
was 
0 higher 
(0.03 lower to 
0.03 higher)
163 (2 studies) +  +  -  -  
Low (1) (2)
Number treated  
for NAS  
Objective 
Follow-up: 15 to 
18 weeks
Study population RR 1.22 
(0.89 to 1.67)
166 (3 studies) +  -  -  -  
Very low (1) (2) (5)447 per 1000 546 per 1000 
(398 to 747)
Moderate
466 per 1000 569 per 1000 
(415 to 778)
Apgar, activity, pulse, grimace, appearance and respiration score; CI, confidence interval; NAS, neonatal abstinence syndrome; RR, risk ratio.
GRADE Working Group grades of evidence.
High quality: Futher research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
(1) For incompete outcome data, we judged the studies at high reisk of attrition bias because the attrition rate was high and unbalanced between groups.
(2) Small sample size.
(3) Statistically significant heterogeneity.
(4) No explanation was provided.
(5) Variability in results
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I Discussion
I Summary of the main results
The effectiveness of OST in pregnancy was measured in three 
studies (Fischer et al., 2006; Jones et al., 2005; MOTHER 
Study) comparing methadone with buprenorphine (223 
participants) and one (Fischer et al., 1999) compared 
methadone with SROM (48 participants).
For the women, the dropout rate was lower in the methadone 
group, whereas there was no difference in use of primary 
substance between methadone and buprenorphine. SROM 
seemed superior to methadone in helping women to abstain 
from the use of heroin during pregnancy.
For the newborns, in the comparison between methadone and 
buprenorphine, birth weight was higher in the buprenorphine 
group in the two trials that could be pooled. The third study 
(MOTHER Study) reported that there was no statistically 
significant difference. For the Apgar score, all studies which 
compared methadone with buprenorphine did not find 
significant differences. The studies used a variety of measures 
to assess NAS. For some of them, there were no statistically 
significant differences between groups (number of newborns 
treated for NAS, mean duration of treatment for NAS, total 
number of morphine drops administered), while others were in 
favour of buprenorphine (the NAS peak score over all 
observation days (MOTHER Study), the total amount of 
morphine required to manage NAS and the length of hospital 
stay). The comparison of methadone with SROM did not result 
in any statistically significant difference for birth weight and 
mean duration of NAS. The Apgar score was not considered in 
the study (Fischer et al., 1999).
Only one study (MOTHER Study), which compared methadone 
with buprenorphine, reported side effects: for the woman, no 
statistically significant differences were observed; for the 
newborns, the buprenorphine group showed significantly 
fewer serious side effects.
In the comparison between methadone and SROM, no side 
effects were reported for the woman, whereas one child in the 
methadone group had central apnea and one child in the 
morphine group had obstructive apnea.
Nevertheless, it should be considered that cigarette smoking 
has an effect on newborn babies’ outcomes. Only one study 
(Fischer et al., 1999) reported data on cigarette consumption 
at the start of the study and at delivery. Women smoked a 
mean of 29 cigarettes per day at enrolment in the study and a 
mean of 14 cigarettes per day at delivery. There was no 
statistically significant difference between groups in the 
reduction of cigarettes smoked. This seems to be a relevant 
outcome not considered by most of the included studies. The 
level of nicotine exposure during pregnancy does affect birth 
weight and might also affect NAS.
For the effectiveness of any psychosocial intervention 
combined with agonist maintenance treatment, six studies 
with 457 participants satisfied the criteria for the assessment 
of adding psychosocial interventions to standard agonist 
maintenance treatment (MTT plus counselling) in order to be 
included in the review. The studies were very heterogeneous in 
terms of study objective, types of interventions compared, 
types of outcome and outcome measurements. They have 
been grouped into three categories: studies on the CM 
approach (three studies), studies on the cognitive behavioural 
approach (two studies) and studies on therapeutic workplace 
approach (one study). All studies assessed the efficacy of the 
addition of a further psychosocial approach to standard care 
(methadone maintenance treatment and counselling).
The dropout rate was not significantly different in all three 
comparisons. For drug use, the CM approach seemed to be 
efficacious in reducing drug use in one study only. Drug use 
was not significantly different between groups in studies 
assessing the efficacy of a cognitive behavioural approach. 
The study assessing the efficacy of the therapeutic workplace 
did not assess this outcome.
Obstetric outcomes were not assessed in the included 
studies. One study on the efficacy of CM assessed these 
outcomes for the infants. Women in the enhanced programme 
tended to have heavier infants than women in standard 
treatment. However, there were no differences in length of 
time the infants remained in hospital for detoxification.
I Quality of the evidence
Regarding the effectiveness of agonist maintenance 
treatment, three out of four studies had an adequate 
allocation concealment and were double blinded. The major 
uncertainty with the results of the studies is for attrition bias: 
three out of four studies had a high dropout rate of between 
30 % and 40 %, unbalanced between groups. Of course this is 
because of the distinctive condition of this target population.
On the effectiveness of any psychosocial intervention 
combined with agonist maintenance treatment, only two 
studies were able to perform an adequate method of random 
sequence generation. Four studies were judged at low risk of 
attrition bias and two at unclear risk. None of the studies was 
‘double blinded’ (see box ‘What is a bias?’ on page 6). 
Furthermore, information on whether the outcome assessor 
was blinded was not specified in any of the studies and overall 
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advised to switch to methadone unless they are not 
responding well to their current treatment. In opioid-
dependent pregnant women, the buprenorphine mono 
formulation should be used in preference to the 
buprenorphine/naloxone formulation.’
(WHO, 2014)
Psychosocial interventions, when taken together, are not 
associated with greater retention in treatment or illicit drug 
abstinence. There are no data on the impact of psychosocial 
interventions on neonatal and obstetric outcomes. 
Nevertheless, the guidelines consider psychosocial 
interventions as an integral component of treatment 
(regardless of the type of medication selected for the OST).
We still need large RCTs comparing different pharmacological 
maintenance treatments with longer follow-up periods (ideally 
up to 1 year) which consider also the level of nicotine 
exposure, the concomitant use during pregnancy of other 
prescribed medications (such as selective serotonin reuptake 
inhibitors, benzodiazepines) and non-prescribed drugs, 
including cocaine, alcohol and marijuana. Moreover, studies 
should be carried out to assess the effectiveness of 
psychosocial treatments in adjunct with pharmacological 
treatments versus pharmacological treatments alone. We 
need large RCTs with obstetric and neonatal end points, as 
well as with longer follow-up periods, in order to examine 
whether or not psychosocial interventions help pregnant 
women with illicit drug dependence. Ideally these studies 
would have multiple sites in order to capture a greater 
diversity of study patients, which would increase the 
generalisability of the findings. 
Nevertheless, as it is considered important to offer more 
options to patients entering or remaining in treatment, it is 
worthwhile to point out that after many years of methadone 
being the only indication for the treatment of opioid-
dependent pregnant women, buprenorphine has now been 
shown to be acceptable and to create less severe NAS for 
newborns. This characteristic in particular may help overcome 
possible resistance by patients and carers, in order to 
encourage opioid-dependent pregnant women in treatment. 
Studies of pregnant women are complex for several reasons, 
including ethical and practical difficulties. It is therefore crucial 
that we exhaustively analyse all elements of existing studies in 
order to add to the discussion. 
the methodological information available in the articles did not 
enter into details, but this can be owing to the lack of space 
allowed by the editors. We searched for unpublished studies 
but we did not find any.
I Conclusions
The pharmacological interventions studied in this overview 
were methadone, buprenorphine and SROM. The observed 
differences between the three approaches did not show a 
homogeneous and comprehensive pattern that would allow us 
to conclude that one treatment is superior to the others for all 
relevant outcomes. While methadone seems superior in 
retaining patients in treatment, buprenorphine seems to yield 
to less severe NAS and higher birth weight. In addition, the 
recently published multicentre international trial on 175 
pregnant women is still too small to draw firm conclusions 
about the equivalence of the treatments compared. Many 
questions remain unanswered, such as which is the most 
effective drug treatment and at what dosage, what is the most 
appropriate type of setting and, especially, whether or not it is 
useful to associate any type of psychosocial intervention to 
pharmacological treatment. 
Although conducted before the publication of the World 
Health Organization’s guidelines on pregnant women (WHO, 
2014), our results are consistent with the recommendations 
included therein. In fact, these guidelines affirm that 
methadone and buprenorphine are equally effective in the 
treatment of opioid-dependent pregnant women. The two 
pharmacological approaches differ, with methadone resulting 
in better maternal retention in treatment and buprenorphine 
may result in milder NAS, fewer preterm deliveries and higher 
birth weight.
The guidelines, based on the consensus of the experts 
involved, recommend that:
‘opioid-dependent pregnant women who are already 
taking opioid maintenance therapy with methadone 
should not be advised to switch to buprenorphine due 
to the risk of opioid withdrawal. Pregnant opioid-
dependent women taking buprenorphine should not be 
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m
ea
su
re
s 
C
ar
ro
ll 
et
 a
l.,
 
1
9
9
5
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
B
lin
d
n
e
ss
 n
o
t 
p
o
ss
ib
le
.
N
=
2
0
 p
re
g
n
an
t w
o
m
e
n
 e
n
ro
lle
d
 a
n
d
 
14
 a
ss
ig
n
e
d
 t
o
 m
et
h
a
d
o
n
e 
m
ai
n
te
n
an
ce
. (
1
)7
 (
2
)7
. M
e
an
 a
g
e 
2
7.
6
 
ye
ar
s;
 7
8
.6
 %
 n
o
n
-m
in
o
ri
ty
 (1
1
/1
4
); 
7
8
.6
 %
 s
in
g
le
; 1
0
0
 %
 u
n
e
m
p
lo
ye
d
; 8
 
(±
6
) 
w
e
e
ks
 g
e
st
at
io
n
al
 a
g
e 
u
p
o
n
 e
n
tr
y 
in
to
 M
M
T;
 m
e
an
 2
.7
 d
ay
s 
co
ca
in
e 
u
se
 
in
 p
as
t 3
0
 d
ay
s.
 E
xc
lu
si
o
n
: >
 2
8
 w
e
e
ks
 
p
re
g
n
an
t.
U
S
A
F
o
r 
al
l d
ai
ly
 M
M
T,
 w
e
e
kl
y 
g
ro
u
p
 c
o
u
n
se
lli
n
g
, t
h
re
e 
ti
m
e
s/
w
e
e
k 
u
ri
n
e 
to
xi
co
lo
g
y 
sc
re
e
n
in
g
. (
1
) 
w
e
e
kl
y 
p
re
n
at
al
 c
la
ss
e
s,
 w
e
e
kl
y 
re
la
p
se
 p
re
ve
n
ti
o
n
 g
ro
u
p
s,
 c
h
ild
ca
re
 d
u
ri
n
g 
tr
e
at
m
e
n
t v
is
it
s,
 a
n
d
 
C
M
 a
w
ar
d
s 
–
 $
1
5
/w
e
e
k 
fo
r 
th
re
e 
co
n
se
cu
ti
ve
 n
e
g
at
iv
e 
u
ri
n
e 
sc
re
e
n
s.
 (
2
) 
M
M
T
 a
n
d
 w
e
e
kl
y 
g
ro
u
p
 c
o
u
n
se
lli
n
g
. 
N
o
 d
iff
e
re
n
ce
 b
et
w
e
e
n
 g
ro
u
p
s 
in
 t
e
rm
s 
o
f M
M
T
 d
o
se
 (m
e
an
 
5
0
 m
g
).
D
u
ra
ti
o
n
: a
ve
ra
g
e 
2
3
 w
e
e
ks
 (r
an
g
e 
1
3
–
3
1
 w
e
e
ks
). 
O
u
tp
at
ie
n
ts
.
A
tt
e
n
d
an
ce
 w
as
 m
e
as
u
re
d
 in
 t
e
rm
s 
o
f 
%
 n
u
m
b
e
r 
o
f g
ro
u
p
s 
at
te
n
d
e
d
. I
n
fa
n
t 
o
u
tc
o
m
e
s 
m
e
as
u
re
d
 a
s 
m
e
an
 
g
e
st
at
io
n
al
 a
g
e 
at
 d
e
liv
e
ry
, m
e
an
 
w
e
ig
h
t a
n
d
 m
e
an
 n
u
m
b
e
r 
o
f d
ay
s 
in
 
h
o
sp
it
al
. U
ri
n
e 
to
xi
co
lo
g
y 
w
as
 
m
e
as
u
re
 a
s 
%
 p
o
si
ti
ve
 f
o
r 
co
ca
in
e,
 
o
p
ia
te
s 
o
r 
o
th
e
r 
d
ru
g
s.
F
is
ch
er
 e
t 
al
., 
1
9
9
9
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
O
p
e
n
.
N
=
4
8
 p
re
g
n
an
t a
d
u
lt
s;
 m
e
an
 a
g
e 
2
6
 
ye
ar
s;
 3
9
.6
 %
 u
n
m
ar
ri
e
d
; d
u
ra
ti
o
n
 o
f 
o
p
io
id
 d
e
p
e
n
d
e
n
ce
: m
e
an
 5
7.
2
 
m
o
n
th
s.
 M
e
an
 g
e
st
at
io
n
al
 a
g
e 
at
 
e
n
tr
y:
 2
2
 w
e
e
ks
.
In
cl
u
si
o
n
 c
ri
te
ri
a:
 o
p
io
id
-d
e
p
e
n
d
e
n
t 
an
d
 p
o
ly
su
b
st
an
ce
 a
b
u
se
 p
re
g
n
an
t 
fe
m
al
e
s 
m
e
et
in
g 
D
S
M
-I
V
 c
ri
te
ri
a
.
A
u
st
ri
a
(1
) 
o
ra
l m
et
h
a
d
o
n
e 
(2
4
 p
ar
ti
ci
p
an
ts
) 
ve
rs
u
s 
(2
) 
o
ra
l s
lo
w
-r
e
le
as
e 
m
o
rp
h
in
e 
(2
4
 p
ar
ti
ci
p
an
ts
) 
af
te
r 
an
 in
d
u
ct
io
n
 p
e
ri
o
d
 o
f 1
0
 d
ay
s.
 
A
t d
e
liv
e
ry
 m
e
an
 m
et
h
a
d
o
n
e 
d
o
se
 w
as
 5
3
.4
8
 m
g
, m
e
an
 
m
o
rp
h
in
e 
d
o
se
 w
as
 3
0
0
.4
3
 m
g
. O
u
tp
at
ie
n
t. 
F
o
llo
w
-u
p
 m
e
an
: 1
5
 
w
e
e
ks
.
N
e
o
n
at
al
 o
u
tc
o
m
e
s:
 f
o
et
al
 d
is
tr
e
ss
; 
b
ir
th
 w
e
ig
h
t; 
N
A
S
 (
F
in
n
e
g
an
 s
ca
le
).
M
at
e
rn
al
 o
u
tc
o
m
e
s:
 r
et
e
n
ti
o
n
; c
o
ca
in
e 
an
d
 b
e
n
zo
d
ia
ze
p
in
e 
co
n
su
m
p
ti
o
n
 
(u
ri
n
e 
an
al
ys
is
); 
o
p
io
id
 u
se
 
(i
d
e
n
ti
fic
at
io
n
 o
f i
n
je
ct
io
n
 s
it
e
s 
fo
r 
m
o
rp
h
in
e
-m
ai
n
ta
in
e
d
 g
ro
u
p
 a
n
d
 u
ri
n
e 
an
al
ys
is
 f
o
r 
m
et
h
a
d
o
n
e
-m
ai
n
ta
in
e
d
 
g
ro
u
p)
.
F
is
ch
er
 e
t 
al
., 
2
0
0
6
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
D
o
u
b
le
-b
lin
d
.
N
=1
8
 p
re
g
n
an
t a
d
u
lt
s;
 m
e
an
 a
g
e 
2
5
.9
 
ye
ar
s;
 6
6
.6
 %
 s
in
g
le
; 6
1
.1
 %
 c
o
m
p
le
te
d
 
9
 y
e
ar
s 
o
f e
d
u
ca
ti
o
n
; d
u
ra
ti
o
n
 o
f 
h
e
ro
in
 c
o
n
su
m
p
ti
o
n
: m
e
an
 2
0
.6
 
m
o
n
th
s.
 M
e
an
 g
e
st
at
io
n
al
 a
g
e 
at
 
e
n
tr
y:
 2
4
 w
e
e
ks
.
In
cl
u
si
o
n
 c
ri
te
ri
a:
 o
p
io
id
-d
e
p
e
n
d
e
n
t 
p
re
g
n
an
t f
e
m
al
e
s 
m
e
et
in
g 
D
S
M
-I
V
 
cr
it
e
ri
a
. E
xc
lu
si
o
n
 c
ri
te
ri
a:
 s
e
ve
re
 
so
m
at
ic
 o
r 
o
th
e
r 
se
ve
re
 p
sy
ch
ia
tr
ic
 
d
is
e
as
e
s,
 h
ig
h
-r
is
k 
p
re
g
n
an
cy
.
A
u
st
ri
a
(1
) 
o
ra
l m
et
h
a
d
o
n
e 
(9
 p
ar
ti
ci
p
an
ts
) 
ve
rs
u
s 
(2
) 
o
ra
l b
u
p
re
n
o
rp
h
in
e 
(9
 p
ar
ti
ci
p
an
ts
). 
D
o
se
 o
f m
et
h
a
d
o
n
e 
b
et
w
e
e
n
 4
0
 a
n
d
 1
0
0
 m
g
/
d
ay
; d
o
se
 o
f b
u
p
re
n
o
rp
h
in
e 
b
et
w
e
e
n
 8
 a
n
d
 2
4
 m
g 
/d
ay
. 
O
u
tp
at
ie
n
t. 
F
o
llo
w
-u
p
: m
e
an
 1
6
 w
e
e
ks
.
N
e
o
n
at
al
 o
u
tc
o
m
e
s:
 b
ir
th
 w
e
ig
h
t; 
N
A
S
 
(F
in
n
e
g
an
 s
ca
le
); 
ch
ild
 h
e
al
th
 s
ta
tu
s;
 
A
p
g
ar
 s
co
re
.
M
at
e
rn
al
 o
u
tc
o
m
e
s:
 r
et
e
n
ti
o
n
; 
m
at
e
rn
al
 w
it
h
d
ra
w
al
 s
ym
p
to
m
s 
(W
an
g 
W
it
h
d
ra
w
al
 Q
u
e
st
io
n
n
ai
re
); 
ill
ic
it
 d
ru
g 
u
se
: o
p
io
id
, c
o
ca
in
e,
 
b
e
n
zo
d
ia
ze
p
in
e 
(u
ri
n
e 
an
al
ys
is
).
H
au
g 
et
 a
l.,
 2
0
0
4
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
B
lin
d
n
e
ss
 n
o
t 
p
o
ss
ib
le
.
N
=7
7
 p
re
g
n
an
t o
p
io
id
-d
e
p
e
n
d
e
n
t 
w
o
m
e
n
 e
n
ro
lle
d
 a
n
d
 6
6
 a
ss
ig
n
e
d
 t
o
 
in
te
rv
e
n
ti
o
n
s,
 ≤
 2
6
 w
e
e
ks
’ g
e
st
at
io
n
al
 
ag
e,
 r
e
ce
iv
in
g 
M
M
T
 a
n
d
 ≥
5
 c
ig
ar
et
te
s/
d
ay
. (
1
) 
3
0
 (
2
) 
3
6
. M
e
an
 a
g
e 
2
9
.7
 
ye
ar
s;
 8
4
 %
 A
fr
ic
an
 A
m
e
ri
ca
n
; 7
9
 %
 
si
n
g
le
 o
r 
n
e
ve
r 
m
ar
ri
e
d
; 9
7
 %
 
u
n
e
m
p
lo
ye
d
; 9
4
 %
 le
ss
 t
h
an
 h
ig
h
 
sc
h
o
o
l e
d
u
ca
ti
o
n
. D
S
M
-I
II-
R
: a
ll 
h
e
ro
in
 
d
e
p
e
n
d
e
n
t (
1
0
0
 %
), 
41
 (
3
5
 %
) 
co
ca
in
e 
d
e
p
e
n
d
e
n
t, 
1
0
 (1
6
 %
) 
m
ar
iju
an
a 
d
e
p
e
n
d
e
n
t, 
17
 (
2
7
 %
) 
al
co
h
o
l 
d
e
p
e
n
d
e
n
t, 
al
l (
1
0
0
 %
) 
n
ic
o
ti
n
e 
d
e
p
e
n
d
e
n
t. 
E
xc
lu
si
o
n
: n
o
t s
ta
te
d
.
U
S
A
F
o
r 
al
l M
M
T.
 A
ll 
re
ce
iv
e
d
 $
1
0
 v
o
u
ch
e
r 
af
te
r 
in
it
ia
l b
at
te
ry
 a
n
d
 $
2
0
 
w
h
e
n
 1
0
-w
e
e
k 
in
te
rv
ie
w
 w
as
 c
o
m
p
le
te
d
. M
e
an
 M
M
T
 d
o
se
 6
5
.2
 
m
g
. (
1
) 
fo
u
r 
M
E
T
 s
e
ss
io
n
s 
u
si
n
g 
a 
m
o
d
ifi
ca
ti
o
n
 o
f t
h
e 
P
ro
je
ct
 
M
A
TC
H
 M
E
T
 m
an
u
al
 (
M
ill
e
r 
et
 a
l.,
 1
9
9
5
) 
w
it
h
 t
h
e 
p
ri
m
ar
y 
g
o
al
 t
o
 
as
si
st
 p
ar
ti
ci
p
an
ts
 in
 q
u
it
ti
n
g 
to
b
a
cc
o
 s
m
o
ki
n
g
. V
is
it
 1
: r
ap
p
o
rt
 
b
u
ild
in
g
; v
is
it
 2
 (1
 w
e
e
k 
la
te
r)
: p
e
rs
o
n
al
is
e
d
 f
e
e
d
b
a
ck
 o
n
 p
o
si
ti
ve
 
b
e
h
av
io
u
rs
, n
e
g
at
iv
e 
co
n
se
q
u
e
n
ce
s 
o
f s
m
o
ki
n
g 
an
d
 s
ta
g
e 
o
f 
ch
an
g
e;
 v
is
it
 3
 (w
e
e
k 
4
): 
co
m
m
it
m
e
n
t a
n
d
 p
la
n
 f
o
r 
ch
an
g
e 
d
e
ve
lo
p
e
d
; v
is
it
 4
 (w
e
e
k 
6
): 
b
ar
ri
e
rs
 t
o
 lo
n
g
-t
e
rm
 c
h
an
g
e 
a
d
d
re
ss
e
d
. (
2
) 
In
fo
rm
at
io
n
 le
afl
et
 a
b
o
u
t t
h
e 
ri
sk
 o
f s
m
o
ki
n
g 
fo
r 
th
e 
w
o
m
an
 a
n
d
 t
h
e 
ch
ild
. D
u
ra
ti
o
n
 1
0
 w
e
e
ks
. I
n
p
at
ie
n
ts
 in
 t
h
e 
fir
st
 p
h
as
e,
 t
h
e
n
 o
u
tp
at
ie
n
ts
.
R
et
e
n
ti
o
n
 in
 t
re
at
m
e
n
t a
s 
%
 a
tt
ri
ti
o
n
. 
C
ig
ar
et
te
 c
o
n
su
m
p
ti
o
n
. U
ri
n
e 
to
xi
co
lo
g
y 
d
o
n
e 
at
 t
h
e 
1
0
-w
e
e
k 
fo
llo
w
-u
p
.
EMCDDA PAPERS I Pregnancy and opioid use: strategies for treatment
25 / 34
A
u
th
or
, y
ea
r
S
tu
d
y 
d
es
ig
n
P
ar
ti
ci
p
an
ts
C
ou
n
tr
y
In
te
rv
en
ti
on
O
u
tc
om
e 
m
ea
su
re
s 
J
on
es
 e
t 
al
., 
2
0
0
5
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
D
o
u
b
le
-b
lin
d
.
N
=
3
0
 p
re
g
n
an
t a
d
u
lt
s;
 m
e
an
 a
g
e 
3
0
.1
 
ye
ar
s;
 7
5
 %
 A
fr
ic
an
 A
m
e
ri
ca
n
, 2
0
 %
 
w
h
it
e,
 5
 %
 o
th
e
r;
 5
5
 %
 u
n
e
m
p
lo
ye
d
 
se
e
ki
n
g
, 4
0
 %
 u
n
e
m
p
lo
ye
d
 n
o
t 
se
e
ki
n
g
, 5
 %
 h
o
m
e
m
ak
e
r;
 m
e
an
 y
e
ar
s 
o
f e
d
u
ca
ti
o
n
 1
0
.2
; c
o
ca
in
e 
u
se
: p
as
t 
3
0
 d
ay
s 
7
5
 %
; o
p
io
id
 u
se
: >
4
 x
 d
ay
 
5
5
 %
; m
e
an
 g
e
st
at
io
n
al
 a
g
e 
at
 e
n
tr
y:
 
2
3
 w
e
e
ks
In
cl
u
si
o
n
 c
ri
te
ri
a:
 e
st
im
at
e
d
 
g
e
st
at
io
n
al
 a
g
e 
o
f 1
6
–
3
0
 w
e
e
ks
; 
o
p
io
id
-d
e
p
e
n
d
e
n
t p
re
g
n
an
t f
e
m
al
e
s 
m
e
et
in
g 
D
S
M
-I
V
 c
ri
te
ri
a
. E
xc
lu
si
o
n
 
cr
it
e
ri
a:
 c
u
rr
e
n
t d
ia
g
n
o
si
s 
o
f a
lc
o
h
o
l 
ab
u
se
 o
r 
d
e
p
e
n
d
e
n
ce
; s
e
lf-
re
p
o
rt
e
d
 
u
se
 o
f b
e
n
zo
d
ia
ze
p
in
e
s;
 s
e
ri
o
u
s 
m
e
d
ic
al
 il
ln
e
ss
; d
ia
g
n
o
si
s 
o
f p
re
te
rm
 
la
b
o
u
r;
 e
vi
d
e
n
ce
 o
f f
o
et
al
 
m
al
fo
rm
at
io
n
; p
o
si
ti
ve
 H
IV
 t
e
st
.
U
S
A
(1
) 
O
ra
l m
et
h
a
d
o
n
e 
(1
5
 p
ar
ti
ci
p
an
ts
) 
ve
rs
u
s 
(2
) 
o
ra
l 
b
u
p
re
n
o
rp
h
in
e 
(1
5
 p
ar
ti
ci
p
an
ts
). 
D
o
se
 o
f m
et
h
a
d
o
n
e:
 m
e
an
 
6
0
 m
g
/d
ay
; d
o
se
 o
f b
u
p
re
n
o
rp
h
in
e:
 m
e
an
 1
2
 m
g
/d
ay
. S
et
ti
n
g
: 
in
p
at
ie
n
t. 
F
o
llo
w
-u
p
 m
e
an
: 1
8
 w
e
e
ks
.
N
e
o
n
at
al
 o
u
tc
o
m
e
s:
 N
u
m
b
e
r 
o
f 
n
e
o
n
at
e
s 
tr
e
at
e
d
 f
o
r 
N
A
S
; p
e
ak
s 
o
f 
N
A
S
 s
co
re
; l
e
n
g
th
 o
f n
e
o
n
at
al
 
h
o
sp
it
al
is
at
io
n
; b
ir
th
 w
e
ig
h
t, 
ch
ild
 
h
e
al
th
 s
ta
tu
s;
 A
p
g
ar
 s
co
re
.
M
at
e
rn
al
 o
u
tc
o
m
e
s:
 r
et
e
n
ti
o
n
; i
lli
ci
t 
d
ru
g 
u
se
 (u
ri
n
e 
an
al
ys
is
).
J
on
es
 e
t 
al
., 
2
0
11
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
B
lin
d
n
e
ss
 n
o
t 
p
o
ss
ib
le
.
N
=
8
5
 p
re
g
n
an
t w
o
m
e
n
 o
n
 M
M
T,
 
g
re
at
e
r 
th
an
 a
g
e 
1
8
, m
e
et
in
g 
D
S
M
-I
I-
R
 
cr
it
e
ri
a 
fo
r 
o
p
ia
te
 d
e
p
e
n
d
e
n
ce
 w
it
h
 
co
ca
in
e 
ab
u
se
, a
d
m
it
te
d
 f
o
r 
fir
st
 t
im
e 
fo
r 
su
b
st
an
ce
 a
b
u
se
 t
re
at
m
e
n
t. 
(1
) 
4
7
 
(2
) 
3
8
. M
e
an
 a
g
e 
2
8
 y
e
ar
s;
 m
e
an
 
g
e
st
at
io
n
al
 a
g
e 
2
3
.4
 w
e
e
ks
; 9
6
 %
 
u
n
e
m
p
lo
ye
d
; 8
5
 %
 s
in
g
le
/n
e
ve
r 
m
ar
ri
e
d
; 7
6
 %
 A
fr
ic
an
 A
m
e
ri
ca
n
; 2
0
 %
 
ch
ro
n
ic
 m
e
d
ic
al
 c
o
n
d
it
io
n
s;
 D
S
M
-I
II-
R
: 
1
0
0
 %
 o
p
ia
te
 d
e
p
e
n
d
e
n
t, 
6
9
 %
 
co
ca
in
e,
 5
 %
 m
ar
iju
an
a,
 1
0
 %
 a
lc
o
h
o
l.
U
S
A
Tr
e
at
m
e
n
t c
o
n
si
st
e
d
 o
f g
ro
u
p
 c
o
u
n
se
lli
n
g 
an
d
 a
t l
e
as
t o
n
ce
-a
-
w
e
e
k 
in
d
iv
id
u
al
 p
sy
ch
o
th
e
ra
p
y 
an
d
 M
M
T;
 m
e
an
 d
o
se
 4
2
 m
g 
fo
r 
al
l. 
(1
) 
M
o
n
e
y 
vo
u
ch
e
rs
 c
o
u
ld
 b
e 
e
ar
n
e
d
 f
o
r 
sp
e
ci
fic
 t
ar
g
et
 
b
e
h
av
io
u
r:
 a
tt
e
n
d
 a
t l
e
as
t 4
 h
o
u
rs
’ c
o
u
n
se
lli
n
g 
an
d
 (d
ay
s 
8
-1
4
) 
p
ro
vi
d
e 
a 
co
ca
in
e
-n
e
g
at
iv
e 
u
ri
n
e 
sa
m
p
le
. (
2
) 
N
o
 v
o
u
ch
e
r 
in
ce
n
ti
ve
s.
D
u
ra
ti
o
n
 2
 w
e
e
ks
. F
ir
st
 w
e
e
k 
in
p
at
ie
n
ts
, t
h
e
n
 o
u
tp
at
ie
n
ts
 
(7
 d
ay
s/
w
e
e
k,
 6
.5
 h
o
u
rs
/d
ay
).
A
tt
e
n
d
an
ce
 w
as
 m
e
as
u
re
d
 a
s 
m
e
an
 
fu
ll-
d
ay
 a
tt
e
n
d
an
ce
 a
s 
w
e
ll 
as
 ‘p
e
rf
e
ct
 
tr
e
at
m
e
n
t a
tt
e
n
d
an
ce
’ d
e
fin
e
d
 a
s 
at
te
n
d
an
ce
 o
n
 a
t l
e
as
t 1
3
 o
r 
14
 f
u
ll 
d
ay
s 
o
f t
re
at
m
e
n
t. 
R
et
e
n
ti
o
n
 w
as
 
m
e
as
u
re
d
 a
s 
th
e 
%
 d
ro
p
o
u
t. 
U
ri
n
e 
sa
m
p
le
s 
w
e
re
 c
o
lle
ct
e
d
 d
ai
ly
 f
ro
m
 
d
ay
s 
8
 t
o
 1
4
 a
n
d
 r
e
p
o
rt
e
d
 a
s 
%
 
p
o
si
ti
ve
.
M
O
T
H
E
R
 S
tu
d
y 
M
u
lt
ic
e
n
tr
e 
ra
n
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
D
o
u
b
le
-b
lin
d
, 
d
o
u
b
le
 d
u
m
m
y.
N
=1
7
5
 p
re
g
n
an
t a
d
u
lt
s,
 1
3
1
 a
ss
ig
n
e
d
 
to
 in
te
rv
e
n
ti
o
n
s;
 M
e
an
 a
g
e 
2
7.
3
 y
e
ar
s;
 
8
3
.2
 %
 w
h
it
e;
 e
m
p
lo
ye
d
 1
3
.3
 %
; m
e
an
 
e
st
im
at
e
d
 g
e
st
at
io
n
al
 a
g
e 
o
f f
o
et
u
s 
1
8
.6
 w
e
e
ks
, m
e
an
 y
e
ar
s 
o
f e
d
u
ca
ti
o
n
 
11
.3
; s
u
b
st
an
ce
 u
se
: h
e
ro
in
 p
re
vi
o
u
s 
3
0
 d
ay
s 
1
0
.2
 %
, c
o
ca
in
e 
p
re
vi
o
u
s 
3
0
 
d
ay
s 
4
.8
 %
, a
n
y 
al
co
h
o
l p
re
vi
o
u
s 
3
0
 
d
ay
s 
0
.4
, %
 b
e
n
zo
d
ia
ze
p
in
e
s 
p
re
vi
o
u
s 
3
0
 d
ay
s 
0
.8
 %
.
In
cl
u
si
o
n
 c
ri
te
ri
a:
 o
p
io
id
-d
e
p
e
n
d
e
n
t 
w
o
m
e
n
 b
et
w
e
e
n
 t
h
e 
ag
e
s 
o
f 1
8
 a
n
d
 
41
 y
e
ar
s 
w
it
h
 a
 s
in
g
le
to
n
 p
re
g
n
an
cy
 
b
et
w
e
e
n
 6
 a
n
d
 3
0
 w
e
e
ks
 o
f g
e
st
at
io
n
.
E
xc
lu
si
o
n
 c
ri
te
ri
a:
 n
o
 m
e
d
ic
al
 o
r 
o
th
e
r 
co
n
d
it
io
n
s 
co
n
tr
ai
n
d
ic
at
in
g 
p
ar
ti
ci
p
at
io
n
; p
e
n
d
in
g 
le
g
al
 a
ct
io
n
; 
d
is
o
rd
e
rs
 r
e
la
te
d
 t
o
 t
h
e 
u
se
 o
f 
b
e
n
zo
d
ia
ze
p
in
e
s 
o
r 
al
co
h
o
l; 
p
la
n
n
in
g 
to
 g
iv
e 
b
ir
th
 o
u
ts
id
e 
th
e 
h
o
sp
it
al
 a
t t
h
e 
st
u
d
y 
si
te
.
U
n
it
e
d
 
S
ta
te
s,
 
A
u
st
ri
a,
 
C
an
a
d
a
(1
) 
S
u
b
lin
g
u
al
 t
ab
le
ts
 o
f b
u
p
re
n
o
rp
h
in
e 
(5
8
 p
ar
ti
ci
p
an
ts
) 
vs
. (
2
) 
o
ra
l m
et
h
a
d
o
n
e 
(7
3
 p
ar
ti
ci
p
an
ts
). 
F
le
xi
b
le
 d
o
se
 r
an
g
e 
o
f 2
 t
o
 
3
2
 m
g 
o
f b
u
p
re
n
o
rp
h
in
e;
 d
o
se
 r
an
g
e 
o
f 2
0
–
14
0
 m
g 
o
f 
m
et
h
a
d
o
n
e
. S
et
ti
n
g
: o
u
tp
at
ie
n
ts
. F
o
llo
w
-u
p
: u
p
 t
o
 1
0
 d
ay
s 
af
te
r 
d
e
liv
e
ry
.
N
e
o
n
at
al
 o
u
tc
o
m
e 
m
e
as
u
re
s:
 
n
e
o
n
at
e
s 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t f
o
r 
N
A
S
, 
p
e
ak
 N
A
S
 s
co
re
, t
o
ta
l a
m
o
u
n
t o
f 
m
o
rp
h
in
e 
n
e
e
d
e
d
 f
o
r 
tr
e
at
m
e
n
t o
f 
N
A
S
, l
e
n
g
th
 o
f h
o
sp
it
al
 s
ta
y,
 h
e
a
d
 
ci
rc
u
m
fe
re
n
ce
, n
u
m
b
e
r 
o
f d
ay
s 
d
u
ri
n
g 
w
h
ic
h
 m
e
d
ic
at
io
n
 w
as
 g
iv
e
n
 f
o
r 
N
A
S
, 
w
e
ig
h
t a
n
d
 le
n
g
th
 a
t b
ir
th
, p
re
te
rm
 
b
ir
th
, g
e
st
at
io
n
al
 a
g
e 
at
 d
e
liv
e
ry
 a
n
d
 
1
-m
in
u
te
 a
n
d
 5
-m
in
u
te
, A
p
g
ar
 s
co
re
s.
M
at
e
rn
al
 o
u
tc
o
m
e
s:
 c
a
e
sa
re
an
 
se
ct
io
n
, w
e
ig
h
t g
ai
n
, a
b
n
o
rm
al
 f
o
et
al
 
p
re
se
n
ta
ti
o
n
 d
u
ri
n
g 
d
e
liv
e
ry
, 
an
a
e
st
h
e
si
a 
d
u
ri
n
g 
d
e
liv
e
ry
, t
h
e 
re
su
lt
s 
o
f d
ru
g 
sc
re
e
n
in
g 
at
 d
e
liv
e
ry
, 
m
e
d
ic
al
 c
o
m
p
lic
at
io
n
s 
at
 d
e
liv
e
ry
, 
st
u
d
y 
d
is
co
n
ti
n
u
at
io
n
, a
m
o
u
n
t o
f 
vo
u
ch
e
r 
m
o
n
e
y 
e
ar
n
e
d
 f
o
r 
d
ru
g
-
n
e
g
at
iv
e 
te
st
s,
 a
n
d
 n
u
m
b
e
r 
o
f 
p
re
n
at
al
 o
b
st
et
ri
c 
vi
si
ts
. A
d
ve
rs
e 
e
ve
n
ts
 f
o
r 
ch
ild
 a
n
d
 m
o
th
e
rs
.
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A
u
th
or
, y
ea
r
S
tu
d
y 
d
es
ig
n
P
ar
ti
ci
p
an
ts
C
ou
n
tr
y
In
te
rv
en
ti
on
O
u
tc
om
e 
m
ea
su
re
s 
O
’N
ei
ll 
et
 a
l.,
 
1
9
9
6
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
B
lin
d
n
e
ss
 n
o
t 
p
o
ss
ib
le
.
N
=
9
2
 p
re
g
n
an
t w
o
m
e
n
 e
n
ro
lle
d
 in
 
M
M
T
 w
h
o
 in
je
ct
e
d
 d
ru
g
s.
 (1
) 
4
7
 (
2
) 
4
5
. 
M
e
an
 a
g
e 
2
6
.2
 y
e
ar
s;
 m
e
an
 y
e
ar
s 
e
d
u
ca
ti
o
n
 1
0
.2
; 5
3
 %
 e
ve
r 
se
x 
w
o
rk
e
r;
 
m
e
an
 g
e
st
at
io
n
al
 a
g
e 
2
2
 w
e
e
ks
; 
D
S
M
-I
II-
R
: 8
5
 %
 o
p
ia
te
 d
e
p
e
n
d
e
n
t, 
1
5
 %
 c
o
ca
in
e,
 5
9
 %
 m
ar
iju
an
a,
 3
2
 %
 
al
co
h
o
l, 
9
8
 %
 n
ic
o
ti
n
e
.
A
u
st
ra
lia
A
ll 
p
ar
ti
ci
p
an
ts
 r
e
ce
iv
e
d
 M
M
T
 (m
e
an
 m
et
h
a
d
o
n
e 
d
o
se
 4
9
 m
g
) 
an
d
 c
o
u
n
se
lli
n
g 
ab
o
u
t H
IV
 r
is
k.
 (1
) 
S
ix
 s
e
ss
io
n
s 
o
f m
an
u
al
-b
as
e
d
 
co
g
n
it
iv
e 
b
e
h
av
io
u
ra
l r
e
la
p
se
 p
re
ve
n
ti
o
n
 t
h
e
ra
p
y 
ai
m
e
d
 a
t 
av
o
id
in
g 
b
e
h
av
io
u
rs
 a
t r
is
k 
fo
r 
H
IV
 in
fe
ct
io
n
 (n
e
e
d
le
 s
h
ar
in
g 
an
d
 
u
n
sa
fe
 s
ex
) 
la
st
in
g 
6
0
–
9
0
 m
in
u
te
s.
 (
2
) 
N
o
 in
te
rv
e
n
ti
o
n
.
D
u
ra
ti
o
n
 3
6
 w
e
e
ks
. O
u
tp
at
ie
n
ts
.
R
et
e
n
ti
o
n
 w
as
 m
e
as
u
re
d
 a
s 
a 
p
ro
p
o
rt
io
n
. A
tt
e
n
d
an
ce
 w
as
 m
e
as
u
re
d
 
as
 t
h
e 
av
e
ra
g
e 
n
u
m
b
e
r 
o
f m
is
se
d
 
ap
p
o
in
tm
e
n
ts
.
S
ilv
er
m
an
 e
t 
al
., 
2
0
0
1
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
B
lin
d
n
e
ss
 n
o
t 
p
o
ss
ib
le
.
N
=
4
0
 p
re
g
n
an
t, 
u
n
e
m
p
lo
ye
d
, w
o
m
e
n
 
1
8
–
5
0
 y
e
ar
s 
o
ld
 o
n
 M
M
T,
 a
n
d
 w
it
h
 
p
o
si
ti
ve
 u
ri
n
e 
to
xi
co
lo
g
y 
fo
r 
o
p
ia
te
s 
w
it
h
in
 6
 w
e
e
ks
 p
ri
o
r 
to
 e
n
ro
lm
e
n
t. 
(1
) 
2
0
 (
2
) 
2
0
. M
e
an
 a
g
e 
3
2
 y
e
ar
s;
 8
3
 %
 
A
fr
ic
an
 A
m
e
ri
ca
; 6
5
 %
 h
ig
h
 s
ch
o
o
l o
r 
g
re
at
e
r 
e
d
u
ca
ti
o
n
; 7
.5
 %
 m
ar
ri
e
d
; 
1
0
0
 %
 u
n
e
m
p
lo
ye
d
; 1
0
0
 %
 u
se
d
 
co
ca
in
e;
 E
xc
lu
si
o
n
: a
t r
is
k 
fo
r 
su
ic
id
e,
 
p
sy
ch
ia
tr
ic
 d
is
o
rd
e
r.
U
S
A
F
o
r 
al
l p
ar
ti
ci
p
an
ts
, s
u
b
st
an
ce
 a
b
u
se
 c
o
u
n
se
lli
n
g 
an
d
 M
M
T
 
p
ro
vi
d
e
d
. D
et
ai
ls
 o
f c
o
u
n
se
lli
n
g 
n
o
t g
iv
e
n
. N
o
 m
e
n
ti
o
n
 o
f M
M
T
 
d
o
se
s 
o
r 
sc
h
e
d
u
le
. (
1
) 
Th
e
ra
p
e
u
ti
c 
w
o
rk
p
la
ce
 3
 h
o
u
rs
/d
ay
 f
o
r 
6
 
m
o
n
th
s.
 J
o
b
 s
ki
lls
 t
ra
in
in
g 
p
ro
vi
d
e
d
. B
as
e
-p
ay
 v
o
u
ch
e
r 
g
iv
e
n
 o
u
t 
at
 t
h
e 
e
n
d
 o
f s
h
if
t. 
E
n
tr
an
ce
 t
o
 w
o
rk
p
la
ce
 c
o
n
ti
n
g
e
n
t u
p
o
n
 
n
e
g
at
iv
e 
u
ri
n
e 
sa
m
p
le
. J
o
b
 s
ki
lls
 f
o
cu
se
d
 o
n
 d
at
a 
e
n
tr
y.
 V
o
u
ch
e
rs
 
u
se
d
 t
o
 p
ro
m
o
te
 a
b
st
in
e
n
ce
 a
n
d
 m
ai
n
ta
in
 w
o
rk
p
la
ce
 a
tt
e
n
d
an
ce
. 
(2
) 
‘R
o
u
ti
n
e’
 d
ru
g 
tr
e
at
m
e
n
t s
e
rv
ic
e
s 
p
ro
vi
d
e
d
 b
y 
th
e 
ce
n
tr
e
. 
D
et
ai
ls
 n
o
t g
iv
e
n
.
D
u
ra
ti
o
n
 2
4
 w
e
e
ks
. F
ir
st
 w
e
e
k 
in
p
at
ie
n
ts
, t
h
e
n
 o
u
tp
at
ie
n
ts
.
R
et
e
n
ti
o
n
 in
 t
re
at
m
e
n
t d
e
fin
e
d
 a
s 
re
m
ai
n
in
g 
in
 t
h
e 
st
u
d
y 
th
ro
u
g
h
 2
4
 
w
e
e
ks
 a
n
d
 r
e
p
o
rt
e
d
 a
s 
N
 a
n
d
 %
. U
ri
n
e 
to
xi
co
lo
g
y 
re
p
o
rt
e
d
 a
s 
%
 n
e
g
at
iv
e 
o
ve
r 
to
ta
l s
tu
d
y 
p
e
ri
o
d
 f
o
r 
e
a
ch
 g
ro
u
p
, a
n
d
 
re
p
o
rt
e
d
 a
s 
o
ve
ra
ll 
p
o
si
ti
ve
 a
n
d
 
d
ru
g
-s
p
e
ci
fic
 p
o
si
ti
ve
. A
tt
e
n
d
an
ce
 in
 
th
e
ra
p
e
u
ti
c 
w
o
rk
p
la
ce
 w
as
 c
al
cu
la
te
d
 
an
d
 p
re
se
n
te
d
 in
 a
 b
ar
 g
ra
p
h
 f
o
r 
e
a
ch
 
in
d
iv
id
u
al
.
Tu
te
n
 e
t 
al
., 
2
0
1
2
R
an
d
o
m
is
e
d
 
co
n
tr
o
lle
d
 t
ri
al
. 
B
lin
d
n
e
ss
 n
o
t 
p
o
ss
ib
le
.
N
=1
4
3
 p
re
g
n
an
t w
o
m
e
n
 w
it
h
 a
n
 
e
st
im
at
e
d
 g
e
st
at
io
n
al
 a
g
e 
o
f l
e
ss
 t
h
an
 
2
8
 w
e
e
ks
 w
h
o
 w
e
re
 o
p
io
id
 d
e
p
e
n
d
e
n
t 
an
d
 m
et
h
a
d
o
n
e 
st
ab
ili
se
d
. A
ve
ra
g
e 
o
f 
3
0
.0
 y
e
ar
s 
o
ld
 (
S
D
=
5
.2
) 
, 7
1
.4
 %
 
A
fr
ic
an
 A
m
e
ri
ca
n
, 6
9
.9
 %
 n
e
ve
r 
m
ar
ri
e
d
, m
e
an
 1
1
.6
 (
S
D
=1
.5
) 
ye
ar
s 
o
f 
e
d
u
ca
ti
o
n
, 6
.0
 %
 c
u
rr
e
n
tl
y 
e
m
p
lo
ye
d
. 
7
2
 %
 u
se
d
 c
o
ca
in
e 
in
 t
h
e 
la
st
 3
0
 d
ay
s,
 
2
1
 %
 u
se
d
 a
lc
o
h
o
l i
n
 t
h
e 
la
st
 3
0
 d
ay
s.
 
E
xc
lu
si
o
n
: n
o
t r
e
ce
iv
in
g 
m
et
h
a
d
o
n
e 
m
ai
n
te
n
an
ce
, n
o
n
-c
o
m
p
lia
n
t w
it
h
 
st
u
d
y 
o
r 
C
e
n
tr
e 
fo
r 
A
d
d
ic
ti
o
n
 
P
re
g
n
an
cy
 p
ro
ce
d
u
re
s,
 h
a
d
 a
 
m
is
ca
rr
ia
g
e 
o
r 
te
rm
in
at
e
d
 t
h
e 
p
re
g
n
an
cy
, t
ra
n
sf
e
rr
e
d
 p
ro
g
ra
m
m
e
s 
o
r 
h
a
d
 a
 n
e
g
at
iv
e 
p
re
g
n
an
cy
 t
e
st
.
U
S
A
A
ll 
p
at
ie
n
ts
 r
e
ce
iv
e
d
 g
ro
u
p
 a
n
d
 in
d
iv
id
u
al
 c
o
u
n
se
lli
n
g
, o
b
st
et
ri
c 
ca
re
, m
e
n
ta
l h
e
al
th
 t
re
at
m
e
n
t a
n
d
 t
ra
n
sp
o
rt
at
io
n
 a
ss
is
ta
n
ce
. (
1
) 
E
sc
al
at
in
g 
re
in
fo
rc
e
m
e
n
t c
o
n
d
it
io
n
, e
ar
n
e
d
 a
 $
7.
5
0
 v
o
u
ch
e
r 
fo
r 
th
e 
fir
st
 o
p
io
id
-n
e
g
at
iv
e 
an
d
 c
o
ca
in
e
-n
e
g
at
iv
e 
u
ri
n
e 
sa
m
p
le
 
su
b
m
it
te
d
. V
al
u
e 
o
f v
o
u
ch
e
r 
in
cr
e
as
e
d
 b
y 
$
1
/d
ay
 o
n
 t
h
e 
sp
e
ci
m
e
n
 c
o
lle
ct
io
n
 d
ay
s 
u
n
ti
l d
e
liv
e
ry
 o
r 
u
n
ti
l t
h
e 
p
ar
ti
ci
p
an
t 
re
a
ch
e
d
 $
4
2
.5
0
 in
 e
ar
n
in
g
s,
 a
ft
e
r 
w
h
ic
h
 e
ar
n
in
g
s 
w
e
re
 c
ap
p
e
d
 
an
d
 r
e
m
ai
n
e
d
 c
o
n
st
an
t a
t t
h
is
 a
m
o
u
n
t. 
If
 r
e
la
p
se
 o
cc
u
rr
e
d
, t
h
e
re
 
w
as
 n
o
 r
e
w
ar
d
 f
o
r 
p
o
si
ti
ve
 u
ri
n
e 
sa
m
p
le
 a
n
d
 t
h
e 
va
lu
e 
o
f t
h
e 
vo
u
ch
e
r 
w
as
 r
e
se
t t
o
 $
7.
5
0
. P
ar
ti
ci
p
an
ts
 e
ar
n
e
d
 v
o
u
ch
e
rs
 u
n
ti
l 
d
e
liv
e
ry
. (
2
) 
F
ix
e
d
 r
e
in
fo
rc
e
m
e
n
t c
o
n
d
it
io
n
, p
ar
ti
ci
p
an
ts
 r
e
ce
iv
e
d
 
a 
$
2
5
 v
o
u
ch
e
r 
e
a
ch
 t
im
e 
th
e
y 
p
ro
vi
d
e
d
 a
 d
ru
g
-n
e
g
at
iv
e 
u
ri
n
e 
sa
m
p
le
. P
ar
ti
ci
p
an
ts
 w
h
o
 r
e
m
ai
n
e
d
 d
ru
g 
ab
st
in
e
n
t t
h
ro
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I Annex 2
I Search strategies
Cochrane Drugs and Alcohol Group Register of Trials search strategy
diagnosis=opioid* OR opiate* AND Pregnan* [TI, AB]
CENTRAL search strategy
 1.  MeSH descriptor: [Opioid-Related Disorders] explode all trees  
 2.  ((drug or substance) near (abuse* or addict* or dependen* or disorder*)):ti,ab,kw  (Word variations have been searched)
 3.  ((opioid* or opiate*) near (abuse* or addict* or dependen*)):ti,ab,kw (Word variations have been searched)
 4. #1 or #2 or #3
 5.  MeSH descriptor: [Heroin] explode all trees
 6.  (opioid* or opiate* or opium or heroin):ti,ab,kw  (Word variations have been searched)
 7.  MeSH descriptor: [Methadone] explode all trees
 8.  “methadone”:ti,ab,kw  (Word variations have been searched)
 9.  MeSH descriptor: [Buprenorphine] explode all trees
10.  “buprenorphine”:ti,ab,kw  (Word variations have been searched)
11.  “codeine”:ti,ab,kw  (Word variations have been searched)
12.  “morphine”:ti,ab,kw  (Word variations have been searched
13.  “LAAM”:ti,ab,kw  (Word variations have been searched)
14. #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
15.  MeSH descriptor: [Pregnancy] explode all trees
16.  pregnant:ti,ab,kw (Word variations have been searched)
17.  “mother”:ti,ab,kw (Word variations have been searched)
18. #15 or #16 or #17
19. #4 and #14 and #18
PubMed search strategy
 1.  “Opioid-Related Disorders”[MeSh]
 2.  ((opioid* OR opiate*) AND (abuse* OR addict* OR dependen*))
 3.  ((drug OR substance) AND (abuse* OR addict* OR dependen* OR disorder*))
 4.  #1 OR #2 OR #3
 5.  Heroin[MeSH]
 6.  heroin[tiab]
 7.  (opioid* OR opiate* OR opium)
 8.  methadone[MeSH] OR methadone[tiab]
 9.  #5 OR #6 OR #7 OR #8
10.  pregnan*[tiab]
11.  “Pregnancy”[Mesh]
12.  “Pregnancy Complications”[Mesh]
13.  mother*[tiab]
14.  #10 OR #11 OR #12 OR #13
15.  randomized controlled trial [pt]
16.  controlled clinical trial [pt]
17.  randomized [tiab]
18.  placebo [tiab]
19.  drug therapy [sh]
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20.  randomly [tiab]
21.  trial [tiab]
22.  groups [tiab]
23.  #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
24.  animals [mh] NOT humans [mh]
25.  #23 NOT #24
26.  #4 AND #9 AND #14 AND #25
CINAHL search strategy
 S1  (MH “Substance Use Disorders+”)
 S2  TX(drug N3 addict*) or TX(drug N3 dependen*) or TX(drug N3 abuse*) or TX(drug N3 misus*) or TX(drug N3 use*)
 S3  TX(substance N3 addict*) or TX(substance N3 dependen*) or TX(substance N3 abuse*) or TX(substance N3 misus*)
 S4  TX(opioid* N3 addict*) or TX(opioid* N3 dependen*) or TX(opioid* N3 abuse*) orTX(opiate* N3 addict*) or TX(opiate* N3 
dependen*) or TX(opiate* N3 abuse*)
 S5  S1 or S2 or S3 or S4
 S6  MH “Heroin”
 S7  TX heroin
 S8  TX (opioid* or opiate*)
 S9  opium
S10  (MH “Methadone”)
S11  TX methadone
S12  S6 or S7 or S8 or S9 or S10
S13  (MH “Pregnancy+”)
S14  TI pregnan* or AB pregnan* or TI mother* or AB mother*
S15  (MH “Pregnancy Complications+”)
S16  S13 or S14 or S15
S17  MH “Clinical Trials+”
S18  PT Clinical trial
S19  TI clinic* N1 trial* or AB clinic* N1 trial*
S20  TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S21  AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S22  TI randomi?ed control* trial* or AB randomi?ed control* trial*
S23  MH “Random Assignment”
S24  TI random* allocat* or AB random* allocat*
S25  MH “Placebos”
S26  TI placebo* or AB placebo*
S27  MH “Quantitative Studies”
S28  S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27
S29  S5 AND S12 AND S16 AND S28
EMBASE search strategy
 1.  ‘addiction’/exp
 2.  ‘drug abuse’/exp
 3.  ((drug OR substance OR opioid* OR opiat*) NEXT/5 (abuse* OR addict* OR depend* OR disorder*)):ab,ti
 4.  #1 OR #2 OR #3
 5.  opioid*:ab,ti OR opiat*:ab,ti OR opium:ab,ti OR heroin*:ab,ti OR narcot*:ab,ti
 6.  ‘methadone’/exp OR methadone:ab,ti OR ‘buprenorphine’/exp OR buprenorphine:ab,ti OR ‘codeine’/exp OR codeine:ab,ti OR 
‘diamorphine’/exp OR morphine:ab,ti OR laam:ab,ti
 7.  #5 OR #6
 8.  ‘pregnancy’/exp OR ‘pregnancy complication’/exp OR pregnan*:ab,ti
 9.  mother*:ab,ti
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10.  #8 OR #9
11.  ‘crossover procedure’/exp OR ‘double-blind procedure’/exp OR ‘single blind procedure’/exp OR ‘controlled clinical trial’/exp 
OR ‘clinical trial’/exp OR placebo:ab,ti OR ‘double-blind’:ab,ti OR ‘single blind’:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR 
volunteer*:ab,ti OR random*:ab,ti OR factorial*:ab,ti ORcrossover:ab,ti OR (cross:ab,ti AND over:ab,ti) OR ‘randomized 
controlled trial’/exp
12.  #4 AND #7 AND #10 AND #11
Web of Science search strategy
Timespan=2007-06-01 - 2013-03-18. Databases=SCI-EXPANDED, SSCI, A&HCI.
Topic=(((opioid* OR opiate* OR opium OR heroin OR methadone) same (abuse* or addict* or dependen* or disorder*))) AND 
Topic=((pregnan* OR mother*)) AND Topic=((randomi* OR randomly OR placebo* OR trial*))
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I Annex 3
I Criteria for risk of bias assessment
Item Judgement Description
1.  Random sequence 
generation 
(selection bias) 
Low risk The investigators describe a random component in the sequence generation process, such as random 
number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing 
dice; drawing of lots; minimisation.
High risk The investigators describe a non-random component in the sequence generation process, such as odd or 
even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgement of the 
clinician; results of a laboratory test or a series of tests; availability of the intervention.
Unclear risk Insufficient information about the sequence generation process to permit judgement of low or high risk.
2.  Allocation 
concealment 
(selection bias) 
Low risk Investigators enrolling participants could not foresee assignment because one of the following, or an 
equivalent method, was used to conceal allocation: central allocation (including telephone, web-based and 
pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; 
sequentially numbered opaque, sealed envelopes.
High risk Investigators enrolling participants could possibly foresee assignments because one of the following methods 
was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without 
appropriate safeguards (e.g. if envelopes were unsealed or non- opaque or not sequentially numbered); 
alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.
Unclear risk Insufficient information to permit judgement of low or high risk. This is usually the case if the method of 
concealment is not described or not described in sufficient detail to allow a definite judgement.
3.  Blinding of 
participants and 
providers 
(performance bias)  
Objective outcomes 
Low risk No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be 
influenced by lack of blinding.
Blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been 
broken.
High risk No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding.
Blinding of key study participants and personnel attempted, but it is likely that the blinding could have been 
broken, and the outcome is likely to be influenced by lack of blinding. 
Unclear risk Insufficient information to permit judgement of low or high risk.
4.  Blinding of 
participants and 
providers 
(performance bias)  
Subjective 
outcomes
Low risk Blinding of participants and providers and it is unlikely that the blinding could have been broken.
High risk No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding.
Blinding of key study participants and personnel attempted, but likely that the blinding could have been 
broken, and the outcome is likely to be influenced by lack of blinding. 
Unclear risk Insufficient information to permit judgement of low or high risk.
5.  Blinding of outcome 
assessor (detection 
bias)  
Objective outcomes 
Low risk No blinding of outcome assessment, but the review authors judge that the outcome measurement is not 
likely to be influenced by lack of blinding.
Blinding of outcome assessment ensured, and it is unlikely that the blinding could have been broken.
6.  Blinding of outcome 
assessor (detection 
bias)  
Subjective 
outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the outcome measurement is not 
likely to be influenced by lack of blinding.
Blinding of outcome assessment ensured, and it is unlikely that the blinding could have been broken.
High risk No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of 
blinding.
Blinding of outcome assessment, but it is likely that the blinding could have been broken, and the outcome 
measurement is likely to be influenced by lack of blinding.
Unclear risk Insufficient information to permit judgement of low or high risk.
7.  Incomplete outcome 
data (attrition bias)  
For all outcomes 
except retention in 
treatment or drop 
out
Low risk No missing outcome data.
Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring 
unlikely to be introducing bias).
Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing 
data across groups.
For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is 
not enough to have a clinically relevant impact on the intervention effect estimate.
For continuous outcome data, plausible effect size (difference in means or standardised difference in 
means) among missing outcomes is not enough to have a clinically relevant impact on observed effect size.
Missing data have been imputed using appropriate methods.
All randomised patients are reported/analysed in the group they were allocated to by randomisation 
irrespective of non-compliance and co-interventions (intention to treat).
High risk Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or 
reasons for missing data across intervention groups.
For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk 
enough to induce clinically relevant bias in intervention effect estimate.
For continuous outcome data, plausible effect size (difference in means or standardised difference in 
means) among missing outcomes is enough to induce clinically relevant bias in observed effect size.
‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at 
randomisation. 
Unclear risk Insufficient information to permit judgement of low or high risk (e.g. number randomised not stated, no 
reasons for missing data provided; number of dropouts not reported for each group).
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I Annex 4
I Forest plot of comparisons
FIGURE A1
Methadone vs. buprenorphine, outcome: dropout.
Study or subgroup
Methadone Buprenorphine
Weight
Risk ratio
M-H, fixed, 95 % CI
Risk ratio
M-H, fixed, 95 % CIEvents Total Events Total
Fischer et al., 2006 3 9 1 9 2.8 % 3.00 (0.38–23.58)
Jones et al., 2005 4 15 6 15 16.9 % 0.67 (0.23–1.89)
MOTHER Study 16 89 28 86 80.3 % 0.55 (0.32–0.95)
Total (95 % CI) 113 110 100.0 % 0.64 (0.41–1.01)
Total events 23 35
Heterogenety Chi2 = 2.44, df = 2 (P = 0.29), I2 = 18 %
Test for overall effect Z = 1.91 (P = 0.06)
FIGURE A2
Methadone vs. buprenorphine, outcome: use of primary substance
Study or subgroup
Methadone Buprenorphine
Weight
Risk ratio
M-H, fixed, 95 % CI
Risk ratio
M-H, fixed, 95 % CIEvents Total Events Total
Jones et al., 2005 1 11 0 9 8.9 % 2.50 (0.11–54.87)
MOTHER Study 11 73 5 58 91.1 % 1.75 (0.64–4.75)
Total (95 % CI) 84 67 100.0 % 1.81 (0.70–4.69)
Total events 12 5
Heterogenety Chi2 = 0.05, df = 1 (P = 0.83), I2 = 0 %
Test for overall effect Z = 1.23 (P = 0.22)
FIGURE A3
Methadone vs. buprenorphine, outcome: birth weight
Study or subgroup
Methadone Buprenorphine
Weight
Mean difference
IV, fixed, 95 % CI
Mean difference
IV, fixed, 95 % CIMean SD Total Mean SD Total
Jones et al., 2005 3,000 120 11 3,530 162 8 3.1 % -530.00 (-662.78 to -397.22)
MOTHER Study 2,878 66 73 3,093 72 58 96.9 % -215,00 (-238.93 to -191,07)
Total (95 % CI) 84 68 100.0 % -224.91 (-248.46 to -201.36)
Heterogenety Chi2 = 20.94, df = 1 (P < 0.00001), I2 = 95 %
Test for overall effect Z = 18.72 (P < 0.00001)
FIGURE A4
Methadone vs. buprenorphine, outcome: Apgar score
Study or subgroup
Methadone Buprenorphine
Weight
Mean difference
IV, fixed, 95 % CI
Mean difference
IV, fixed, 95 % CIMean SD Total Mean SD Total
Jones et al., 2005 8.9 0.09 11 8.9 0.15 10 8,6 % 0.00 (-0.11 to 0.11)
MOTHER Study 9 0.1 73 9 0.1 69 91,4 % 0.00 (-0.03 to 0.03)
Total (95 % CI) 84 79 100.0 % 0.00 (-0,03 to 0.03)
Heterogenety Chi2 = 0.00, df = 1 (P = 1.00), I2 = 0 %
Test for overall effect Z = 0.00 (P = 1.00)
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FIGURE A5
Methadone vs. buprenorphine, outcome: number treated for NAS
Study or subgroup
Methadone Buprenorphine
Weight
Risk ratio
M-H, fixed, 95 % CI
Risk ratio
M-H, fixed, 95 % CIEvents Total Events Total
Fischer et al., 2006 3 6 5 8 11.8 % 0.80 (0.31–2.10)
Jones et al., 2005 5 11 2 10 5.7 % 2.27 (0.56–9.20)
MOTHER Study 41 73 27 58 82.5 % 1.21 (0.86–1.70)
Total (95 % CI) 90 76 100.0 % 1.22 (0.89–1.67)
Total events 49 34
Heterogenety Chi2 = 1.50, df = 2 (P = 0.47), I2 = 0 %
Test for overall effect Z = 1.24 (P=0.22)
FIGURE A6
Methadone vs. buprenorphine, outcome: mean duration of NAS treatment
Study or subgroup
Methadone Buprenorphine
Weight
Mean difference
IV, fixed, 95 % CI
Mean difference
IV, fixed, 95 % CIMean SD Total Mean SD Total
Fischer et al., 2006 5.3 1.5 6 4.8 2.9 8 0.0 % 0.50 (-1.84 to 2.84)
MOTHER Study 9 0.1 73 9 0.1 58 100.0 % 0.00 (-0,03 to 0.03)
Total (95 % CI) 79 66 100.0 % 0.00 (-0.03 to 0.03)
Heterogenety Chi2 = 0.18, df = 1 (P = 0.68), I2 = 0 %
Test for overall effect Z = 0.01 (P = 1.00)
FIGURE A7
Methadone vs. buprenorphine, outcome: total amount of morphine for NAS
Study or subgroup
Methadone Buprenorphine
Weight
Mean difference
IV, fixed, 95 % CI
Mean difference
IV, fixed, 95 % CIMean SD Total Mean SD Total
Fischer et al., 2006 2.71 1.68 6 2 2 8 9.4 % 0.71 (-1.22 to 2.64)
MOTHER Study 10.4 2.6 73 1.1 0.7 58 90.6 % 9.30 (8.68–9.92)
Total (95 % CI) 79 66 100.0 % 8.49 (7.90–9.08)
Heterogenety Chi2 = 68.87, df = 1 (P < 0.00001), I2 = 99 %
Test for overall effect Z = 28.06 (P < 0.00001)
FIGURE A8
Methadone vs. buprenorphine, outcome: length of hospital stay
Study or subgroup
Methadone Buprenorphine
Weight
Mean difference
IV, fixed, 95 % CI
Mean difference
IV, fixed, 95 % CIMean SD Total Mean SD Total
Jones et al., 2005 8.1 0.78 11 6.8 0.86 10 30.1 % 1.30 (0.60–2.00)
MOTHER Study 17.5 1.5 73 10.8 1.2 58 69.9 % 6.70 (6.24–7.16)
Total (95 % CI) 84 68 100.0 % 5.07 (4.69–5.46)
Heterogenety Chi2 = 157.69, df = 1 (P < 0.00001), I2 = 99 %
Test for overall effect Z = 25.73 (P < 0.00001)
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FIGURE A9
Contingency management versus control, outcome: drop out
Study or subgroup
Methadone Buprenorphine
Weight
Risk ratio
M-H, fixed, 95 % CI
Risk ratio
M-H, fixed, 95 % CIEvents Total Events Total
Jones et al., 2011 3 47 2 38 17.1 % 1.21 (0.21–6.89)
Tuten et al., 2012 12 52 4 22 43.6 % 1.27 (0.46–3.51)
Tuten et al., 2012 11 38 4 22 39.3 % 1.59 (0.58–4.40)
Total (95 % CI) 137 82 100.0 % 1.39 (0.71–2.69)
Total events 26 10
Heterogenety Chi2 = 0.12, df = 2 (P = 0.94), I2 = 0 %
Test for overall effect Z = 0.97 (P =0.33)
FIGURE A10
Manual-based interventions versus control, outcome: drop out
Study or subgroup
Methadone Buprenorphine
Weight
Risk ratio
M-H, fixed, 95 % CI
Risk ratio
M-H, fixed, 95 % CIEvents Total Events Total
Haug et al., 2004 4 30 5 33 48.2 % 0.88 (0.26–2.98)
O’Neill et al., 1996 7 47 5 45 51.8 % 1.34 (0.46–3.92)
Total (95 % CI) 77 78 100.0 % 1.12 (0.50–2.49)
Total events 11 10
Heterogenety Chi2 = 0.26, df = 1 (P = 0.61), I2 = 0 %
Test for overall effect Z = 0.27 (P =0.78)
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